80 results on '"Aoshi T"'
Search Results
2. Crystal structure of the Fab fragment of murine monoclonal antibody KH-1 against Human herpesvirus 6B
- Author
-
Nishimura, M., primary, Novita, B.D., additional, Kato, T., additional, Tjan, L.H., additional, Wang, B., additional, Wakata, A., additional, Poetranto, A.L., additional, Kawabata, A., additional, Tang, H., additional, Aoshi, T., additional, and Mori, Y., additional
- Published
- 2020
- Full Text
- View/download PDF
3. Crystal structure of the Fab fragment of murine monoclonal antibody OHV-3 against Human herpesvirus 6B
- Author
-
Nishimura, M., primary, Novita, B.D., additional, Kato, T., additional, Tjan, L.H., additional, Wang, B., additional, Wakata, A., additional, Poetranto, A.L., additional, Kawabata, A., additional, Tang, H., additional, Aoshi, T., additional, and Mori, Y., additional
- Published
- 2020
- Full Text
- View/download PDF
4. γδ T cell-mediated activation of cDC1 orchestrates CD4 + Th1 cell priming in malaria.
- Author
-
Ibraheem Y, Bayarsaikhan G, Macalinao ML, Kimura K, Yui K, Aoshi T, and Inoue SI
- Subjects
- Animals, Mice, Mice, Inbred C57BL, Receptors, CXCR3 metabolism, Receptors, Antigen, T-Cell, gamma-delta metabolism, Receptors, Antigen, T-Cell, gamma-delta immunology, Receptors, CCR7 metabolism, Receptors, CCR7 immunology, Signal Transduction, Spleen immunology, Cell Differentiation immunology, Female, Th1 Cells immunology, Dendritic Cells immunology, Dendritic Cells metabolism, Lymphocyte Activation immunology, Malaria immunology, Malaria parasitology
- Abstract
γδ T cells facilitate the CD4
+ T helper 1 (Th1) cell response against Plasmodium infection by activating conventional dendritic cells (cDCs), although the underlying mechanism remains elusive. Our study revealed that γδ T cells promote the complete maturation and production of interleukin-12 and CXCR3-ligands specifically in type 1 cDCs (cDC1), with minimal impact on cDC2 and monocyte derived DCs (Mo-DCs). During the initial infection phase, γδ T cell activation and temporal accumulation in the splenic white pulp, alongside cDC1, occur via CCR7-signaling. Furthermore, cDC1/γδ T cell interactions in the white pulp are amplified through CXCR3 signaling in γδ T cells, optimizing Th1 cell priming by cDC1. We also demonstrated how transitional Th1 cells arise in the white pulp before establishing their presence in the red pulp as fully differentiated Th1 cells. Additionally, we elucidate the reciprocal activation between γδ T cells and cDC1s. These findings suggest that Th1 cell priming is orchestrated by this reciprocal activation in the splenic white pulp during the early phase of blood-stage Plasmodium infection., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2024 Ibraheem, Bayarsaikhan, Macalinao, Kimura, Yui, Aoshi and Inoue.)- Published
- 2024
- Full Text
- View/download PDF
5. Sema6D forward signaling impairs T cell activation and proliferation in head and neck cancer.
- Author
-
Hirai T, Naito Y, Koyama S, Nakanishi Y, Masuhiro K, Izumi M, Kuge T, Naito M, Mizuno Y, Yamaguchi Y, Kang S, Yaga M, Futami Y, Nojima S, Nishide M, Morita T, Kato Y, Tsuda T, Takemoto N, Kinugasa-Katayama Y, Aoshi T, Villa JK, Yamashita K, Enokida T, Hoshi Y, Matsuura K, Tahara M, Takamatsu H, Takeda Y, Inohara H, and Kumanogoh A
- Subjects
- Animals, Humans, Mice, Cell Proliferation, Retrospective Studies, Squamous Cell Carcinoma of Head and Neck genetics, Tumor Microenvironment, Head and Neck Neoplasms genetics, Mouth Neoplasms
- Abstract
Immune checkpoint inhibitors (ICIs) are indicated for a diverse range of cancer types, and characterizing the tumor immune microenvironment is critical for optimizing therapeutic strategies, including ICIs. T cell infiltration and activation status in the tumor microenvironment greatly affects the efficacy of ICIs. Here, we show that semaphorin 6D (Sema6D) forward signaling, which is reportedly involved in coordinating the orientation of cell development and migration as a guidance factor, impaired the infiltration and activation of tumor-specific CD8+ T cells in murine oral tumors. Sema6D expressed by nonhematopoietic cells was responsible for this phenotype. Plexin-A4, a receptor for Sema6D, inhibited T cell infiltration and partially suppressed CD8+ T cell activation and proliferation induced by Sema6D stimulation. Moreover, mouse oral tumors, which are resistant to PD-1-blocking treatment in wild-type mice, showed a response to the treatment in Sema6d-KO mice. Finally, analyses of public data sets of human head and neck squamous cell carcinoma, pan-cancer cohorts, and a retrospective cohort study showed that SEMA6D was mainly expressed by nonhematopoietic cells such as cancer cells, and SEMA6D expression was significantly negatively correlated with CD8A, PDCD1, IFNG, and GZMB expression. Thus, targeting Sema6D forward signaling is a promising option for increasing ICI efficacy.
- Published
- 2024
- Full Text
- View/download PDF
6. Linking antigen specific T-cell dynamics in a microfluidic chip to single cell transcription patterns.
- Author
-
Ide H, Aoshi T, Saito M, Espulgar WV, Briones JC, Hosokawa M, Matsunaga H, Arikawa K, Takeyama H, Koyama S, Takamatsu H, and Tamiya E
- Subjects
- Mice, Animals, Antigens, Antigen-Presenting Cells, Lymphocyte Activation, T-Lymphocytes, Microfluidics
- Abstract
A new non-invasive screening profile has been realized that can aid in determining T-cell activation state at single-cell level. Production of activated T-cells with good specificity and stable proliferation is greatly beneficial for advancing adoptive immunotherapy as innate immunological cells are not effective in recognizing and eliminating cancer as expected. The screening method is realized by relating intracellular Ca
2+ intensity and motility of T-cells interacting with APC (Antigen Presenting Cells) in a microfluidic chip. The system is tested using APC pulsed with OVA257-264 peptide and its modified affinities (N4, Q4, T4 and V4), and the T-cells from OT-1 mice. In addition, single cell RNA sequencing reveals the activation states of the cells and the clusters from the derived profiles can be indicative of the T-cell activation state. The presented system here can be versatile for a comprehensive application to proceed with T-cell-based immunotherapy and screen the antigen-specific T-cells with excellent efficiency and high proliferation., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2023 Elsevier Inc. All rights reserved.)- Published
- 2023
- Full Text
- View/download PDF
7. Tumor-derived semaphorin 4A improves PD-1-blocking antibody efficacy by enhancing CD8 + T cell cytotoxicity and proliferation.
- Author
-
Naito Y, Koyama S, Masuhiro K, Hirai T, Uenami T, Inoue T, Osa A, Machiyama H, Watanabe G, Sax N, Villa J, Kinugasa-Katayama Y, Nojima S, Yaga M, Hosono Y, Okuzaki D, Satoh S, Tsuda T, Nakanishi Y, Suga Y, Morita T, Fukushima K, Nishide M, Shiroyama T, Miyake K, Iwahori K, Hirata H, Nagatomo I, Yano Y, Tamiya M, Kumagai T, Takemoto N, Inohara H, Yamasaki S, Yamashita K, Aoshi T, Akbay EA, Hosen N, Shintani Y, Takamatsu H, Mori M, Takeda Y, and Kumanogoh A
- Subjects
- Animals, Humans, Mice, Antibodies, Blocking, CD8-Positive T-Lymphocytes, Cell Proliferation, Programmed Cell Death 1 Receptor, Tumor Microenvironment, Carcinoma, Non-Small-Cell Lung drug therapy, Lung Neoplasms drug therapy, Semaphorins genetics, Semaphorins metabolism
- Abstract
Immune checkpoint inhibitors (ICIs) have caused revolutionary changes in cancer treatment, but low response rates remain a challenge. Semaphorin 4A (Sema4A) modulates the immune system through multiple mechanisms in mice, although the role of human Sema4A in the tumor microenvironment remains unclear. This study demonstrates that histologically Sema4A-positive non-small cell lung cancer (NSCLC) responded significantly better to anti-programmed cell death 1 (PD-1) antibody than Sema4A-negative NSCLC. Intriguingly, SEMA4A expression in human NSCLC was mainly derived from tumor cells and was associated with T cell activation. Sema4A promoted cytotoxicity and proliferation of tumor-specific CD8
+ T cells without terminal exhaustion by enhancing mammalian target of rapamycin complex 1 and polyamine synthesis, which led to improved efficacy of PD-1 inhibitors in murine models. Improved T cell activation by recombinant Sema4A was also confirmed using isolated tumor-infiltrating T cells from patients with cancer. Thus, Sema4A might be a promising therapeutic target and biomarker for predicting and promoting ICI efficacy.- Published
- 2023
- Full Text
- View/download PDF
8. Bronchoalveolar lavage fluid reveals factors contributing to the efficacy of PD-1 blockade in lung cancer.
- Author
-
Masuhiro K, Tamiya M, Fujimoto K, Koyama S, Naito Y, Osa A, Hirai T, Suzuki H, Okamoto N, Shiroyama T, Nishino K, Adachi Y, Nii T, Kinugasa-Katayama Y, Kajihara A, Morita T, Imoto S, Uematsu S, Irie T, Okuzaki D, Aoshi T, Takeda Y, Kumagai T, Hirashima T, and Kumanogoh A
- Subjects
- Bronchoalveolar Lavage Fluid, Humans, Nivolumab pharmacology, Nivolumab therapeutic use, Programmed Cell Death 1 Receptor metabolism, Tumor Microenvironment, Carcinoma, Non-Small-Cell Lung pathology, Lung Neoplasms pathology
- Abstract
Bronchoalveolar lavage is commonly performed to assess inflammation and identify responsible pathogens in lung diseases. Findings from bronchoalveolar lavage might be used to evaluate the immune profile of the lung tumor microenvironment (TME). To investigate whether bronchoalveolar lavage fluid (BALF) analysis can help identify patients with non-small cell lung cancer (NSCLC) who respond to immune checkpoint inhibitors (ICIs), BALF and blood were prospectively collected before initiating nivolumab. The secreted molecules, microbiome, and cellular profiles based on BALF and blood analysis of 12 patients were compared with regard to therapeutic effect. Compared with ICI nonresponders, responders showed significantly higher CXCL9 levels and a greater diversity of the lung microbiome profile in BALF, along with a greater frequency of the CD56+ subset in blood T cells, whereas no significant difference in PD-L1 expression was found in tumor cells. Antibiotic treatment in a preclinical lung cancer model significantly decreased CXCL9 in the lung TME, resulting in reduced sensitivity to anti-PD-1 antibody, which was reversed by CXCL9 induction in tumor cells. Thus, CXCL9 might be associated with the lung TME microbiome, and the balance of CXCL9 and lung TME microbiome could contribute to nivolumab sensitivity in patients with NSCLC. BALF analysis can help predict the efficacy of ICIs when performed along with currently approved examinations.
- Published
- 2022
- Full Text
- View/download PDF
9. Development of combination adjuvant for efficient T cell and antibody response induction against protein antigen.
- Author
-
Haseda Y, Munakata L, Kimura C, Kinugasa-Katayama Y, Mori Y, Suzuki R, and Aoshi T
- Subjects
- Aluminum pharmacology, Animals, Antibody Formation immunology, Cell Movement immunology, Fatty Acids, Monounsaturated pharmacology, Humans, Immunity immunology, Liposomes immunology, Lymph Nodes immunology, Mice, Quaternary Ammonium Compounds pharmacology, T-Lymphocytes, Cytotoxic drug effects, T-Lymphocytes, Cytotoxic immunology, Vaccination methods, Vaccines immunology, Adjuvants, Immunologic pharmacology, Antigens immunology, Proteins immunology, T-Lymphocytes immunology
- Abstract
Most current clinical vaccines work primarily by inducing the production of neutralizing antibodies against pathogens. Vaccine adjuvants that efficiently induce T cell responses to protein antigens need to be developed. In this study, we developed a new combination adjuvant consisting of 1,2-dioleoyl-3-trimethylammonium propane (DOTAP), D35, and an aluminum salt. Among the various combinations tested, the DOTAP/D35/aluminum salt adjuvant induced strong T cell and antibody responses against the model protein antigen with a single immunization. Adjuvant component and model antigen interaction studies in vitro also revealed that the strong mutual interactions among protein antigens and other components were one of the important factors for this efficient immune induction by the novel combination adjuvant. In addition, in vivo imaging of the antigen distribution suggested that the DOTAP component in the combination adjuvant formulation elicited transient antigen accumulation at the draining lymph nodes, possibly by antigen uptake DC migration. These results indicate the potential of the new combination adjuvant as a promising vaccine adjuvant candidate to treat infectious diseases and cancers., Competing Interests: These authors disclose the following: Yasunari Haseda, Lisa Munakata, Ryo Suzuki, Yasuko Mori, and Taiki Aoshi filed a patent application related to the content of this manuscript[Immunostimulants: Patent Application Number(JAPAN) 227061(2018)]. The other authors declare no conflicts of interest.
- Published
- 2021
- Full Text
- View/download PDF
10. HDAC inhibitor, MS-275, increases vascular permeability by suppressing Robo4 expression in endothelial cells.
- Author
-
Kashio T, Shirakura K, Kinoshita M, Morita M, Ishiba R, Muraoka K, Kanbara T, Tanaka M, Funatsu R, Hino N, Koyama S, Suzuki R, Yoshioka Y, Aoshi T, Doi T, and Okada Y
- Subjects
- Animals, Benzamides pharmacology, Histone Deacetylase Inhibitors pharmacology, Mice, Pyridines, Receptors, Cell Surface metabolism, Capillary Permeability, Endothelial Cells metabolism
- Abstract
Roundabout guidance receptor 4 (Robo4) is an endothelial-specific membrane protein that suppresses pathological angiogenesis and vascular hyperpermeability by stabilizing endothelial cells. Robo4 suppresses severe systemic inflammation induced by pathogens and endotoxins and inhibits tumor growth and metastasis, therefore serving as a potential therapeutic target. Although the regulation of Robo4 expression through transcription factors and epigenetic mechanisms has been studied, the role of histone deacetylases (HDACs) has not been explored. In the present study, we investigated the involvement of HDACs in the regulation of Robo4 expression. An HDAC inhibitor, MS-275, which inhibits HDAC1, HDAC2, and HDAC3, was found to suppress Robo4 expression in endothelial cells. Small interfering RNA (siRNA)-mediated knockdown of HDAC3, but not of HDAC1 and 2, also decreased its expression level. MS-275 downregulated the expression of the transcription factor complex GABP, in addition to suppressing Robo4 promoter activity. GABP expression was also downregulated by the siRNA against HDAC3. MS-275 decreased the transendothelial electrical resistance of a monolayer of mouse endothelial cells and increased the rate of leakage of Evans blue dye in the mouse lungs. In addition, MS-275 accelerated cell migration through the endothelial cell monolayer and augmented cell extravasation in the mouse lungs. Taken together, we demonstrated that MS-275 suppresses Robo4 expression by inhibiting HDAC3 in endothelial cells and enhances endothelial and vascular permeability. Thus, we demonstrated a novel mechanism regulating Robo4 expression and vascular permeability, which is anticipated to contribute to future therapies for infectious and inflammatory diseases.
- Published
- 2021
- Full Text
- View/download PDF
11. Microfluidics sorting enables the isolation of an intact cellular pair complex of CD8+ T cells and antigen-presenting cells in a cognate antigen recognition-dependent manner.
- Author
-
Kuwabara S, Tanimoto Y, Okutani M, Jie M, Haseda Y, Kinugasa-Katayama Y, and Aoshi T
- Subjects
- Animals, CD8-Positive T-Lymphocytes metabolism, Cell Communication immunology, Cell Line, Tumor, Flow Cytometry methods, HEK293 Cells, Humans, Mice, Inbred C57BL, Mice, Knockout, Mice, Transgenic, Receptors, Antigen, T-Cell genetics, Receptors, Antigen, T-Cell immunology, Receptors, Antigen, T-Cell metabolism, Reproducibility of Results, Mice, Antigen Presentation immunology, Antigen-Presenting Cells immunology, Antigens immunology, CD8-Positive T-Lymphocytes immunology, Cell Separation methods, Microfluidics methods
- Abstract
Adaptive immune responses begin with cognate antigen presentation-dependent specific interaction between T cells and antigen-presenting cells. However, there have been limited reports on the isolation and analysis of these cellular complexes of T cell-antigen-presenting cell (T/APC). In this study, we successfully isolated intact antigen-specific cellular complexes of CD8+ T/APC by utilizing a microfluidics cell sorter. Using ovalbumin (OVA) model antigen and OT-I-derived OVA-specific CD8+ T cells, we analyzed the formation of antigen-specific and antigen-non-specific T/APC cellular complexes and revealed that the antigen-specific T/APC cellular complex was highly stable than the non-specific one, and that the intact antigen-specific T/APC complex can be retrieved as well as enriched using a microfluidics sorter, but not a conventional cell sorter. The single T/APC cellular complex obtained can be further analyzed for the sequences of T cell receptor Vα and Vβ genes as well as cognate antigen information simultaneously. These results suggested that this approach can be applied for other antigen and CD8+ T cells of mice and possibly those of humans. We believe that this microfluidics sorting method of the T/APC complex will provide useful information for future T cell immunology research., Competing Interests: These authors disclose the following: Soichiro Kuwabara and Mie Okutani are employed by the Research Foundation for Microbial Diseases of Osaka University. The remaining authors declare no conflict of interest.
- Published
- 2021
- Full Text
- View/download PDF
12. Comprehensive Screening of Mouse T-Cell Epitopes in Human Herpesvirus 6B Glycoprotein H/L/Q1/Q2 Tetramer Complex.
- Author
-
Okutani M, Kawabata A, Nishimura M, Nagamata S, Kuwabara S, Haseda Y, Munakata L, Suzuki R, Mori Y, and Aoshi T
- Subjects
- Animals, CD4-Positive T-Lymphocytes immunology, CD8-Positive T-Lymphocytes immunology, Cell Line, Tumor, Humans, Mice, Mice, Inbred BALB C, Mice, Inbred C57BL, Epitopes, T-Lymphocyte immunology, Glycoproteins immunology, Herpesvirus 6, Human immunology, Viral Envelope Proteins immunology
- Abstract
Human herpesvirus 6 (HHV-6) infects over 90% of people. The HHV-6 subtype, HHV-6B in particular, is often associated with exanthem subitum in early childhood. Exanthem subitum is usually self-limiting and good prognosis disease; however, some infants primarily infected with HHV-6B develop encephalitis/encephalopathy, and half of the patients developed encephalopathy reported to have neurological sequelae. Furthermore, after primary infection, HHV-6B remains in a latent state and sometimes reactivated in immunosuppressed patients, causing life-threatening severe encephalopathy. However, effective immunotherapies or vaccines for controlling HHV-6B infection and reactivation have not yet been established. Recently, we have found that the HHV-6B tetrameric glycoprotein (g) complex, gH/gL/gQ1/gQ2 is a promising vaccine candidate, and currently under preclinical development. To confirm our vaccine candidate protein complex induce detectable T-cell responses, in this study, we comprehensively screened CD4
+ and CD8+ T-cell epitopes in the gH/gL/gQ1/gQ2 tetrameric complex protein in mice immunisation model. Both BALB/c and C57BL/6 mice were immunised with the tetrameric complex protein or plasmid DNA encoding gH, gL, gQ1, and gQ2, and then restimulated with 162 20-mer peptides covering the whole gH/gL/gQ1/gQ2 sequences; multiple CD4+ and CD8+ T-cell-stimulating peptides were identified in both BALB/c and C57BL/6 mice. Our study demonstrates that gH/gL/gQ1/gQ2 tetramer-targeted vaccination has potential to induce T-cell responses in two different strains of mice and supports the future development and application of T-cell-inducing vaccine and immunotherapies against HHV-6B., Competing Interests: Mie Okutani and Soichiro Kuwabara are employed by the Research Foundation for Microbial Diseases of Osaka University. Yasunari Haseda, Lisa Munakata, Ryo Suzuki, Yasuko Mori, and Taiki Aoshi have filed a patent application related to the content of this manuscript. The remaining authors declare no conflicts of interest., (Copyright © 2020 Mie Okutani et al.)- Published
- 2020
- Full Text
- View/download PDF
13. Tetrameric glycoprotein complex gH/gL/gQ1/gQ2 is a promising vaccine candidate for human herpesvirus 6B.
- Author
-
Wang B, Hara K, Kawabata A, Nishimura M, Wakata A, Tjan LH, Poetranto AL, Yamamoto C, Haseda Y, Aoshi T, Munakata L, Suzuki R, Komatsu M, Tsukamoto R, Itoh T, Nishigori C, Saito Y, Matozaki T, and Mori Y
- Subjects
- Adjuvants, Immunologic pharmacology, Animals, Exanthema Subitum virology, Herpesvirus 6, Human, Humans, Mice, Mice, Inbred BALB C, Exanthema Subitum immunology, Herpesvirus Vaccines immunology, Viral Envelope Proteins immunology
- Abstract
Primary infection of human herpesvirus 6B (HHV-6B) occurs in infants after the decline of maternal immunity and causes exanthema subitum accompanied by a high fever, and it occasionally develops into encephalitis resulting in neurological sequelae. There is no effective prophylaxis for HHV-6B, and its development is urgently needed. The glycoprotein complex gH/gL/gQ1/gQ2 (called 'tetramer of HHV-6B') on the virion surface is a viral ligand for its cellular receptor human CD134, and their interaction is thus essential for virus entry into the cells. Herein we examined the potency of the tetramer as a vaccine candidate against HHV-6B. We designed a soluble form of the tetramer by replacing the transmembrane domain of gH with a cleavable tag, and the tetramer was expressed by a mammalian cell expression system. The expressed recombinant tetramer is capable of binding to hCD134. The tetramer was purified to homogeneity and then administered to mice with aluminum hydrogel adjuvant and/or CpG oligodeoxynucleotide adjuvant. After several immunizations, humoral and cellular immunity for HHV-6B was induced in the mice. These results suggest that the tetramer together with an adjuvant could be a promising candidate HHV-6B vaccine., Competing Interests: I have read the journal's policy and the authors of this manuscript have the following competing interests: Taiki Aoshi are employed by the Research Foundation for Microbial Diseases of Osaka University. Ryo Suzuki, Taiki Aoshi, and Yasuko Mori have filed a patent application related to the content of this manuscript. The remaining authors declare no conflicts.
- Published
- 2020
- Full Text
- View/download PDF
14. Structural basis for the interaction of human herpesvirus 6B tetrameric glycoprotein complex with the cellular receptor, human CD134.
- Author
-
Nishimura M, Novita BD, Kato T, Handayani Tjan L, Wang B, Wakata A, Lystia Poetranto A, Kawabata A, Tang H, Aoshi T, and Mori Y
- Subjects
- Humans, Herpesvirus 6, Human metabolism, Receptors, OX40 metabolism, Roseolovirus Infections metabolism, Viral Envelope Proteins metabolism
- Abstract
A unique glycoprotein is expressed on the virus envelope of human herpesvirus 6B (HHV-6B): the complex gH/gL/gQ1/gQ2 (hereafter referred to as the HHV-6B tetramer). This tetramer recognizes a host receptor expressed on activated T cells: human CD134 (hCD134). This interaction is essential for HHV-6B entry into the susceptible cells and is a determinant for HHV-6B cell tropism. The structural mechanisms underlying this unique interaction were unknown. Herein we solved the interactions between the HHV-6B tetramer and the receptor by using their neutralizing antibodies in molecular and structural analyses. A surface plasmon resonance analysis revealed fast dissociation/association between the tetramer and hCD134, although the affinity was high (KD = 18 nM) and comparable to those for the neutralizing antibodies (anti-gQ1: 17 nM, anti-gH: 2.7 nM). A competition assay demonstrated that the anti-gQ1 antibody competed with hCD134 in the HHV-6B tetramer binding whereas the anti-gH antibody did not, indicating the direct interaction of gQ1 and hCD134. A single-particle analysis by negative-staining electron microscopy revealed the tetramer's elongated shape with a gH/gL part and extra density corresponding to gQ1/gQ2. The anti-gQ1 antibody bound to the tip of the extra density, and anti-gH antibody bound to the putative gH/gL part. These results highlight the interaction of gQ1/gQ2 in the HHV-6B tetramer with hCD134, and they demonstrate common features among viral ligands of the betaherpesvirus subfamily from a macroscopic viewpoint., Competing Interests: The authors declare no conflicts.
- Published
- 2020
- Full Text
- View/download PDF
15. Murine Cross-Reactive Nonneutralizing Polyclonal IgG1 Antibodies Induced by Influenza Vaccine Inhibit the Cross-Protective Effect of IgG2 against Heterologous Virus in Mice.
- Author
-
Shibuya M, Aoshi T, Kuroda E, and Yoshioka Y
- Subjects
- Animals, Antibodies, Viral classification, Binding, Competitive, Cross Protection, Influenza A Virus, H1N1 Subtype genetics, Influenza Vaccines administration & dosage, Male, Mice, Mice, Inbred C57BL, Orthomyxoviridae Infections prevention & control, Orthomyxoviridae Infections virology, Protein Binding, Protein Isoforms biosynthesis, Protein Isoforms classification, Survival Analysis, Vaccination adverse effects, Adjuvants, Immunologic administration & dosage, Antibodies, Viral biosynthesis, Immunoglobulin G biosynthesis, Influenza A Virus, H1N1 Subtype immunology, Oligodeoxyribonucleotides administration & dosage, Orthomyxoviridae Infections immunology, Vaccination methods
- Abstract
Annual vaccination against influenza viruses is the most reliable and efficient way to prevent and control annual epidemics and protect from severe influenza disease. However, current split influenza vaccines are generally not effective against antigenically mismatched (heterologous) strains. To broaden the protective spectrum of influenza vaccines, adjuvants that can induce cross-reactive antibodies with cross-protection via Fc-mediated effector functions are urgently sought. Although IgG2 antibodies are generally more efficient than IgG1 antibodies in Fc-mediated effector functions, it is not yet clear which IgG isotypes show superior cross-protection against heterologous strains. It also remains unclear whether these IgG isotypes interfere with each other's protective effects. Here, we found that influenza split vaccine adjuvanted with aluminum salts, which predominantly induce cross-reactive IgG1, did not confer cross-protection against heterologous virus challenge in mice. In contrast, split vaccine adjuvanted with CpG oligodeoxynucleotides, which predominantly induce cross-reactive IgG2, showed cross-protection through the interaction of cross-reactive nonneutralizing IgG2 and alveolar macrophages, indicating the importance of cross-reactive nonneutralizing IgG2 for cross-protection. Furthermore, by using serum samples from immunized mice and isolated polyclonal antibodies, we show that vaccine-induced cross-reactive nonneutralizing IgG1 suppress the cross-protective effects of IgG2 by competitively inhibiting the binding of IgG2 to virus. Thus, we demonstrate the new concept that cross-reactive IgG1 may interfere with the potential for cross-protection of influenza vaccine. We propose that adjuvants that selectively induce virus-specific IgG2 in mice, such as CpG oligodeoxynucleotides, are optimal for heterologous protection. IMPORTANCE Current influenza vaccines are generally effective against highly similar virus strains by inducing neutralizing antibodies. However, these antibodies fail to neutralize antigenically mismatched (heterologous) strains and therefore provide limited protection against them. Efforts are being made to develop vaccines with cross-protective ability that would protect broadly against heterologous strains, because the mismatch between predicted and epidemic strains cannot always be avoided, resulting in low vaccine efficacy. Here, we show that nonneutralizing IgG2 antibodies induced by an optimal adjuvant play a crucial role in cross-protection against heterologous virus challenge in mice. Furthermore, nonneutralizing polyclonal IgG1 suppressed the cross-protective effects of nonneutralizing polyclonal IgG2 by competitively blocking the binding of IgG2 to its antigen. These data shed new light on the importance of IgG isotypes and the selection of appropriate adjuvants for the development of universal influenza vaccines. Furthermore, our findings are applicable to the rational design of vaccines against other pathogens., (Copyright © 2020 American Society for Microbiology.)
- Published
- 2020
- Full Text
- View/download PDF
16. Microfluidic-prepared DOTAP nanoparticles induce strong T-cell responses in mice.
- Author
-
Haseda Y, Munakata L, Meng J, Suzuki R, and Aoshi T
- Subjects
- Adjuvants, Immunologic chemistry, Animals, CD4-Positive T-Lymphocytes drug effects, CD4-Positive T-Lymphocytes immunology, CD8-Positive T-Lymphocytes drug effects, CD8-Positive T-Lymphocytes immunology, Humans, Immunity, Cellular immunology, Liposomes pharmacology, Mice, Microfluidics, Nanoparticles chemistry, Vaccines chemistry, Adjuvants, Immunologic pharmacology, Fatty Acids, Monounsaturated pharmacology, Immunity, Cellular drug effects, Quaternary Ammonium Compounds pharmacology, Vaccines pharmacology
- Abstract
For the induction of antigen-specific T-cell responses by vaccination, an appropriate immune adjuvant is required. Vaccine adjuvants generally provide two functions, namely, immune potentiator and delivery, and many adjuvants that can efficiently induce T-cell responses are known to have the combination of these two functions. In this study, we explored a cationic lipid DOTAP-based adjuvant. We found that the microfluidic preparation of DOTAP nanoparticles induced stronger CD4+ and CD8+ T-cell responses than liposomal DOTAP. The further addition of Type-A CpG D35 in DOTAP nanoparticles increased the induction of T-cell responses, particularly in CD4+ T cells. Further investigations revealed that the size of DOTAP nanoparticles, prepared buffer conditions, and physicochemical interaction with vaccine antigen are important factors for the efficient induction of T-cell responses with a relatively small antigen dose. These results suggested that microfluidic-prepared DOTAP nanoparticles plus D35 are a promising adjuvant for a vaccine that induces therapeutic T-cell responses for treating cancer and infectious diseases., Competing Interests: Some of the authors have filed a patent application (Application Number 2018-227061) related to the content of this manuscript. However, this does not alter our adherence to PLOS ONE policies on sharing data and materials.
- Published
- 2020
- Full Text
- View/download PDF
17. Lipid Nanoparticles Potentiate CpG-Oligodeoxynucleotide-Based Vaccine for Influenza Virus.
- Author
-
Shirai S, Shibuya M, Kawai A, Tamiya S, Munakata L, Omata D, Suzuki R, Aoshi T, and Yoshioka Y
- Subjects
- Animals, Antibodies, Viral immunology, Immunization methods, Mice, Mice, Inbred C57BL, Orthomyxoviridae Infections immunology, Vaccination methods, Cytosine immunology, Guanine immunology, Influenza A Virus, H1N1 Subtype immunology, Lipids immunology, Nanoparticles administration & dosage, Oligodeoxyribonucleotides immunology, Phosphates immunology
- Abstract
Current influenza vaccines are generally effective against highly similar (homologous) strains, but their effectiveness decreases markedly against antigenically mismatched (heterologous) strains. One way of developing a universal influenza vaccine with a broader spectrum of protection is to use appropriate vaccine adjuvants to improve a vaccine's effectiveness and change its immune properties. Oligodeoxynucleotides (ODNs) with unmethylated cytosine-phosphate-guanine (CpG) motifs (CpG ODNs), which are Toll-like-receptor 9 (TLR9) agonists, are among the most promising adjuvants and are already being used in humans. However, the development of novel delivery vehicles to improve adjuvant effects in vivo is highly desirable. Here, we assessed the potential of lipid nanoparticles (LNPs) as CpG ODN delivery vehicles in mice to augment the vaccine adjuvant effects of CpG ODN and enhance the protective spectrum of conventional influenza split vaccine (SV). In vitro , compared with CpG ODN, LNPs containing CpG ODNs (LNP-CpGs) induced significantly greater production of cytokines such as IL-12 p40 and IFN-α by mouse dendritic cells (DCs) and significantly greater expression of the co-stimulatory molecules CD80 and CD86 on DCs. In addition, after subcutaneous administration in mice, compared with CpG ODN, LNP-CpGs enhanced the expression of CD80 and CD86 on plasmacytoid DCs in draining lymph nodes. LNP-CpGs given with SV from H1N1 influenza A virus improved T-cell responses and gave a stronger not only SV-specific but also heterologous-virus-strain-specific IgG2c response than CpG ODN. Furthermore, immunization with SV plus LNP-CpGs protected against not only homologous strain challenge but also heterologous and heterosubtypic strain challenge, whereas immunization with SV plus CpG ODNs protected against homologous strain challenge only. We therefore demonstrated that LNP-CpGs improved the adjuvant effects of CpG ODN and broadened the protective spectrum of SV against influenza virus. We expect that this strategy will be useful in developing adjuvant delivery vehicles and universal influenza vaccines., (Copyright © 2020 Shirai, Shibuya, Kawai, Tamiya, Munakata, Omata, Suzuki, Aoshi and Yoshioka.)
- Published
- 2020
- Full Text
- View/download PDF
18. Lipid nanoparticles of Type-A CpG D35 suppress tumor growth by changing tumor immune-microenvironment and activate CD8 T cells in mice.
- Author
-
Munakata L, Tanimoto Y, Osa A, Meng J, Haseda Y, Naito Y, Machiyama H, Kumanogoh A, Omata D, Maruyama K, Yoshioka Y, Okada Y, Koyama S, Suzuki R, and Aoshi T
- Subjects
- Animals, Antineoplastic Agents pharmacology, Blood Cells metabolism, Drug Compounding, Drug Stability, Drug Therapy, Combination, Fatty Acids, Monounsaturated chemistry, Humans, Immunosuppression Therapy, Immunotherapy, Liver metabolism, Mice, Neoplasms drug therapy, Neoplasms, Experimental therapy, Oligodeoxyribonucleotides pharmacology, Phosphatidylethanolamines chemistry, Phosphorylcholine chemistry, Programmed Cell Death 1 Receptor metabolism, Quaternary Ammonium Compounds chemistry, Antineoplastic Agents chemistry, CD8-Positive T-Lymphocytes drug effects, Lipids chemistry, Nanocapsules chemistry, Oligodeoxyribonucleotides chemistry, Tumor Microenvironment drug effects
- Abstract
Type-A CpG oligodeoxynucleotides (ODNs), which have a natural phosphodiester backbone, is one of the highest IFN-α inducer from plasmacytoid dendritic cells (pDC) via Toll-like receptor 9 (TLR9)-dependent signaling. However, the in vivo application of Type-A CpG has been limited because the rapid degradation in vivo results in relatively weak biological effect compared to other Type-B, -C, and -P CpG ODNs, which have nuclease-resistant phosphorothioate backbones. To overcome this limitation, we developed lipid nanoparticles formulation containing a Type-A CpG ODN, D35 (D35LNP). When tested in a mouse tumor model, intratumoral and intravenous D35LNP administration significantly suppressed tumor growth in a CD8 T cell-dependent manner, whereas original D35 showed no efficacy. Tumor suppression was associated with Th1-related gene induction and activation of CD8 T cells in the tumor. The combination of D35LNP and an anti-PD-1 antibody increased the therapeutic efficacy. Importantly, the therapeutic schedule and dose of intravenous D35LNP did not induce apparent liver toxicity. These results suggested that D35LNP is a safe and effective immunostimulatory drug formulation for cancer immunotherapy., (Copyright © 2019 The Authors. Published by Elsevier B.V. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
19. Identification of CD4 and H-2K d -restricted cytotoxic T lymphocyte epitopes on the human herpesvirus 6B glycoprotein Q1 protein.
- Author
-
Nagamata S, Aoshi T, Kawabata A, Yamagishi Y, Nishimura M, Kuwabara S, Murakami K, Yamada H, and Mori Y
- Subjects
- Animals, Antigens, Viral immunology, Cell Line, Glycoproteins immunology, Humans, Interferon-gamma immunology, Mice, Epitopes, T-Lymphocyte immunology, Herpesvirus 6, Human immunology, T-Lymphocytes, Cytotoxic immunology
- Abstract
The identification of Human herpesvirus 6B (HHV-6B) epitopes that are recognized by T-cells could contribute to the development of potential vaccines and immunotherapies. Here, we identified CD4
+ and H-2Kd -restricted CD8+ T-cell epitopes on the glycoprotein Q1 of HHV-6B (BgQ1), which is a unique glycoprotein and essential for HHV-6B viral entry, by using in vivo electroporation with a plasmid DNA encoding BgQ1, overlapping peptides spanning the BgQ1 sequence, ELISPOT assay for quantification of gamma interferon (IFN-γ), and computer-based T-cell epitope prediction programs. The CD4+ and CD8+ T-cell epitopes identified in BALB/c mice in this study could be a good animal model system for use in the development of T-cell responses, inducing HHV-6B vaccines or immunotherapies.- Published
- 2019
- Full Text
- View/download PDF
20. Development of screening method for intranasal influenza vaccine and adjuvant safety in preclinical study.
- Author
-
Hiradate Y, Sasaki E, Momose H, Asanuma H, Furuhata K, Takai M, Aoshi T, Yamada H, Ishii KJ, Tanemura K, Mizukami T, and Hamaguchi I
- Subjects
- Administration, Intranasal, Animals, Drug Evaluation, Preclinical, Female, Mice, Mice, Inbred BALB C, Adjuvants, Immunologic chemistry, Adjuvants, Immunologic pharmacology, Influenza A Virus, H1N1 Subtype chemistry, Influenza A Virus, H1N1 Subtype immunology, Influenza Vaccines chemistry, Influenza Vaccines immunology, Influenza Vaccines pharmacology
- Abstract
Recently, many vaccine adjuvants have been developed; however, most of the newly developed adjuvants have been dropped out of preclinical and clinical trials owing to their unexpected toxicity. Thus, the development of highly quantitative and comparable screening methods for evaluating adjuvant safety is needed. In a previous study, we identified specific biomarkers for evaluating the safety of an intranasal influenza vaccine with CpG K3 adjuvant by comparing biomarker expression. We hypothesized that these biomarkers might be useful for screening newly developed adjuvant safety. We compared the expression of biomarkers in mouse lungs by the intranasal administration of 4 types of adjuvants: Alum, Pam
3 CSK4 , NanoSiO2 , and DMXAA with subvirion influenza vaccine. The control adjuvant alum did not show any significant increase in biomarker expression or preclinical parameters; however, NanoSiO2 and Pam3 CSK4 increased the expression of biomarkers, such as Timp1 and Csf1. DMXAA at 300 μg induced the expression of over 80% of biomarkers. Hierarchical clustering analysis showed that 300 μg DMXAA was classified in the toxicity reference whole-particle influenza vaccine cluster. FACS analysis to confirm specific phenotypes that the number of T cells decreased in DMXAA-treated mouse lungs. Thus, our biomarkers are useful for initial adjuvant safety and toxicity screening., (Copyright © 2018 International Alliance for Biological Standardization. Published by Elsevier Ltd. All rights reserved.)- Published
- 2018
- Full Text
- View/download PDF
21. Carbonate Apatite Nanoparticles Act as Potent Vaccine Adjuvant Delivery Vehicles by Enhancing Cytokine Production Induced by Encapsulated Cytosine-Phosphate-Guanine Oligodeoxynucleotides.
- Author
-
Takahashi H, Misato K, Aoshi T, Yamamoto Y, Kubota Y, Wu X, Kuroda E, Ishii KJ, Yamamoto H, and Yoshioka Y
- Subjects
- Adjuvants, Immunologic chemistry, Animals, Apatites immunology, Cytokines biosynthesis, Drug Carriers chemistry, Humans, Mice, Oligodeoxyribonucleotides administration & dosage, Oligodeoxyribonucleotides immunology, Adjuvants, Immunologic administration & dosage, Apatites administration & dosage, Drug Carriers pharmacology, Nanoparticles, Vaccines immunology
- Abstract
Vaccine adjuvants that can induce not only antigen-specific antibody responses but also Th1-type immune responses and CD8
+ cytotoxic T lymphocyte responses are needed for the development of vaccines against infectious diseases and cancer. Of many available adjuvants, oligodeoxynucleotides (ODNs) with unmethylated cytosine-phosphate-guanine (CpG) motifs are the most promising for inducing the necessary immune responses, and these adjuvants are currently under clinical trials in humans. However, the development of novel delivery vehicles that enhance the adjuvant effects of CpG ODNs, subsequently increasing the production of cytokines such as type-I interferons (IFNs), is highly desirable. In this study, we demonstrate the potential of pH-responsive biodegradable carbonate apatite (CA) nanoparticles as CpG ODN delivery vehicles that can enhance the production of type-I IFNs (such as IFN-α) relative to that induced by CpG ODNs and can augment the adjuvant effects of CpG ODNs in vivo . In contrast to CpG ODNs, CA nanoparticles containing CpG ODNs (designated CA-CpG) induced significant IFN-α production by mouse dendritic cells and human peripheral blood mononuclear cells in vitro ; and production of interleukin-12, and IFN-γ was higher in CA-CpG-treated groups than in CpG ODNs groups. In addition, treatment with CA-CpG resulted in higher cytokine production in draining lymph nodes than did treatment with CpG ODNs in vivo . Furthermore, vaccination with CA-CpG plus an antigen, such as ovalbumin or influenza virus hemagglutinin, resulted in higher antigen-specific antibody responses and CD8+ cytotoxic T lymphocyte responses in vivo , in an interleukin-12- and type-I IFN-dependent manner, than did vaccination with the antigen plus CpG ODNs; in addition, the efficacy of the vaccine against influenza virus was higher with CA-CpG as the adjuvant than with CpG ODNs as the adjuvant. These data show the potential of CA nanoparticles to serve as CpG ODN delivery vehicles that increase the production of cytokines, especially IFN-α, induced by CpG ODNs and thus augment the efficacy of CpG ODNs as adjuvants. We expect that the strategy reported herein will facilitate the design and development of novel adjuvant delivery vehicles for vaccines.- Published
- 2018
- Full Text
- View/download PDF
22. Quantifying the relative immune cell activation from whole tissue/organ-derived differentially expressed gene data.
- Author
-
Wijaya E, Igarashi Y, Nakatsu N, Haseda Y, Billaud J, Chen YA, Mizuguchi K, Yamada H, Ishii K, and Aoshi T
- Subjects
- Animals, Biopsy, DNA Contamination, Databases, Genetic, Gastrointestinal Tract pathology, Human papillomavirus 16 immunology, Humans, Inflammatory Bowel Diseases drug therapy, Infliximab therapeutic use, Mice, Software, Spleen metabolism, Virion immunology, Leukocytes, Mononuclear metabolism, Organ Specificity genetics, Organ Specificity immunology, Transcriptome
- Abstract
Evaluation of immune responses in individual immune cell types is important for the development of new medicines. Here, we propose a computational method designated ICEPOP (Immune CEll POPulation) to estimate individual immune cell type responses from bulk tissue and organ samples. The relative gene responses are scored for each cell type by using the data from differentially expressed genes derived from control- vs drug-treated sample pairs, and the data from public databases including ImmGen and IRIS, which contain gene expression profiles of a variety of immune cells. By ICEPOP, we analysed cell responses induced by vaccine-adjuvants in the mouse spleen, and extended the analyses to human peripheral blood mononuclear cells and gut biopsy samples focusing on human papilloma virus vaccination and inflammatory bowel disease treatment with Infliximab. In both mouse and human datasets, our method reliably quantified the responding immune cell types and provided insightful information, demonstrating that our method is useful to evaluate immune responses from bulk sample-derived gene expression data. ICEPOP is available as an interactive web site ( https://vdynamics.shinyapps.io/icepop/ ) and Python package ( https://github.com/ewijaya/icepop ).
- Published
- 2017
- Full Text
- View/download PDF
23. Development of a Novel Virus-Like Particle Vaccine Platform That Mimics the Immature Form of Alphavirus.
- Author
-
Urakami A, Sakurai A, Ishikawa M, Yap ML, Flores-Garcia Y, Haseda Y, Aoshi T, Zavala FP, Rossmann MG, Kuno S, Ueno R, and Akahata W
- Subjects
- Animals, Disease Models, Animal, Female, Macaca mulatta, Malaria Vaccines administration & dosage, Malaria Vaccines genetics, Male, Mice, Inbred BALB C, Plasmodium falciparum genetics, Plasmodium falciparum immunology, Plasmodium yoelii genetics, Plasmodium yoelii immunology, Protozoan Proteins genetics, Vaccines, Synthetic administration & dosage, Vaccines, Synthetic genetics, Vaccines, Synthetic immunology, Vaccines, Virus-Like Particle administration & dosage, Vaccines, Virus-Like Particle genetics, Chikungunya virus genetics, Drug Carriers, Malaria prevention & control, Malaria Vaccines immunology, Protozoan Proteins immunology, Vaccines, Virus-Like Particle immunology
- Abstract
Virus-like particles (VLPs) are noninfectious multiprotein structures that are engineered to self-assemble from viral structural proteins. Here, we developed a novel VLP-based vaccine platform utilizing VLPs from the chikungunya virus. We identified two regions within the envelope protein, a structural component of chikungunya, where foreign antigens can be inserted without compromising VLP structure. Our VLP displays 480 copious copies of an inserted antigen on the VLP surface in a highly symmetric manner and is thus capable of inducing strong immune responses against any inserted antigen. Furthermore, by mimicking the structure of the immature form of the virus, we altered our VLP's in vivo dynamics and enhanced its immunogenicity. We used the circumsporozoite protein (CSP) of the Plasmodium falciparum malaria parasite as an antigen and demonstrated that our VLP-based vaccine elicits strong immune responses against CSP in animals. The sera from immunized monkeys protected mice from malaria infection. Likewise, mice vaccinated with P. yoelii CSP-containing VLPs were protected from an infectious sporozoite challenge. Hence, our uniquely engineered VLP platform can serve as a blueprint for the development of vaccines against other pathogens and diseases., (Copyright © 2017 Urakami et al.)
- Published
- 2017
- Full Text
- View/download PDF
24. Modes of Action for Mucosal Vaccine Adjuvants.
- Author
-
Aoshi T
- Subjects
- Adjuvants, Immunologic administration & dosage, Administration, Mucosal, Animals, Humans, Vaccines administration & dosage, Adjuvants, Immunologic pharmacology, Immunity, Innate, Immunity, Mucosal, Vaccines immunology
- Abstract
Vaccine adjuvants induce innate immune responses and the addition of adjuvants to the vaccine helps to induce protective immunity in the host. Vaccines utilizing live attenuated or killed whole pathogens usually contain endogenous adjuvants, such as bacterial cell wall products and their genomic nucleic acids, which act as pathogen-associated molecular patterns and are sufficient to induce adaptive immune responses. However, purified protein- or antigen-based vaccines, including component or recombinant vaccines, usually lose these endogenous innate immune stimulators, so the addition of an exogenous adjuvant is essential for the success of these vaccine types. Although this adjuvant requirement is mostly the same for parental and mucosal vaccines, the development of mucosal vaccine adjuvants requires the specialized consideration of adapting the adjuvants to characteristic mucosal conditions. This review provides a brief overview of mucosa-associated immune response induction processes, such as antigen uptake and dendritic cell subset-dependent antigen presentation. It also highlights several mucosal vaccine adjuvants from recent reports, particularly focusing on their modes of action.
- Published
- 2017
- Full Text
- View/download PDF
25. A novel vaccinological evaluation of intranasal vaccine and adjuvant safety for preclinical tests.
- Author
-
Sasaki E, Kuramitsu M, Momose H, Kobiyama K, Aoshi T, Yamada H, Ishii KJ, Mizukami T, and Hamaguchi I
- Subjects
- Administration, Intranasal, Animals, Biomarkers metabolism, Cytokines genetics, Cytokines immunology, Dose-Response Relationship, Immunologic, Drug Evaluation, Preclinical, Female, Gene Expression, Humans, Membrane Transport Proteins genetics, Membrane Transport Proteins immunology, Mice, Mice, Inbred BALB C, Orthomyxoviridae Infections immunology, Orthomyxoviridae Infections virology, Vaccines, Inactivated, Adjuvants, Immunologic administration & dosage, Antibodies, Viral biosynthesis, Influenza Vaccines administration & dosage, Oligodeoxyribonucleotides administration & dosage, Orthomyxoviridae Infections prevention & control
- Abstract
Vaccines are administered to healthy humans, including infants, so the safety and efficacy must be very high. Therefore, evaluating vaccine safety in preclinical and clinical studies, according to World Health Organization guidelines, is crucial for vaccine development and clinical use. A change in the route of administration is considered to alter a vaccine's immunogenicity. Several adjuvants have also been developed and approved for use in vaccines. However, the addition of adjuvants to vaccines may cause unwanted immune responses, including facial nerve paralysis and narcolepsy. Therefore, a more accurate and comprehensive strategy must be used to develope next-generation vaccines for ensuring vaccine safety. Previously, we have developed a system with which to evaluate vaccine safety in rats using a systematic vaccinological approach and 20 marker genes. In this study, we developed a safety evaluation system for nasally administered influenza vaccines and adjuvanted influenza vaccines using these marker genes. Expression of these genes increased dose-dependent manner when mice were intranasally administered the toxicity reference vaccine. When the adjuvant CpG K3 or a CpG-K3-combined influenza vaccine was administered intranasally, marker gene expression increased in a CpG-K3-dose-dependent way. A histopathological analysis indicated that marker gene expression correlated with vaccine- or adjuvant-induced phenotypic changes in the lung and nasal mucosa. We believe that the marker genes expression analyses will be useful in preclinical testing, adjuvant development, and selecting the appropriate dose of adjuvant in nasal administration vaccines., (Copyright © 2016 Elsevier Ltd. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
26. Advax, a Delta Inulin Microparticle, Potentiates In-built Adjuvant Property of Co-administered Vaccines.
- Author
-
Hayashi M, Aoshi T, Haseda Y, Kobiyama K, Wijaya E, Nakatsu N, Igarashi Y, Standley DM, Yamada H, Honda-Okubo Y, Hara H, Saito T, Takai T, Coban C, Petrovsky N, and Ishii KJ
- Subjects
- Animals, Antigens immunology, Biomarkers, Cytokines biosynthesis, Dendritic Cells immunology, Dendritic Cells metabolism, Female, Immunization, Inulin administration & dosage, Liposomes, Lymphocyte Activation, Macrophages immunology, Macrophages metabolism, Male, Mice, Mice, Knockout, Models, Animal, Phagocytosis immunology, Signal Transduction, Th2 Cells immunology, Th2 Cells metabolism, Adjuvants, Immunologic administration & dosage, Inulin analogs & derivatives, Vaccines administration & dosage, Vaccines immunology
- Abstract
Advax, a delta inulin-derived microparticle, has been developed as an adjuvant for several vaccines. However, its immunological characteristics and potential mechanism of action are yet to be elucidated. Here, we show that Advax behaves as a type-2 adjuvant when combined with influenza split vaccine, a T helper (Th)2-type antigen, but behaves as a type-1 adjuvant when combined with influenza inactivated whole virion (WV), a Th1-type antigen. In addition, an adjuvant effect was not observed when Advax-adjuvanted WV vaccine was used to immunize toll-like receptor (TLR) 7 knockout mice which are unable to respond to RNA contained in WV antigen. Similarly, no adjuvant effect was seen when Advax was combined with endotoxin-free ovalbumin, a neutral Th0-type antigen. An adjuvant effect was also not seen in tumor necrosis factor (TNF)-α knockout mice, and the adjuvant effect required the presences of dendritic cells (DCs) and phagocytic macrophages. Therefore, unlike other adjuvants, Advax potentiates the intrinsic or in-built adjuvant property of co-administered antigens. Hence, Advax is a unique class of adjuvant which can potentiate the intrinsic adjuvant feature of the vaccine antigens through a yet to be determined mechanism., (Copyright © 2016 The Authors. Published by Elsevier B.V. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
27. Isoflurane is a suitable alternative to ether for anesthetizing rats prior to euthanasia for gene expression analysis.
- Author
-
Nakatsu N, Igarashi Y, Aoshi T, Hamaguchi I, Saito M, Mizukami T, Momose H, Ishii KJ, and Yamada H
- Subjects
- Animals, Liver, Lung, Male, Pentobarbital, Toxicogenetics, Anesthesia, Anesthetics, Inhalation toxicity, Ether toxicity, Euthanasia, Animal, Isoflurane, Rats, Sprague-Dawley blood, Rats, Sprague-Dawley genetics, Transcriptome
- Abstract
Diethyl ether (ether) had been widely used in Japan for anesthesia, despite its explosive properties and toxicity to both humans and animals. We also had used ether as an anesthetic for euthanizing rats for research in the Toxicogenomics Project (TGP). Because the use of ether for these purposes will likely cease, it is required to select an alternative anesthetic which is validated for consistency with existing TGP data acquired under ether anesthesia. We therefore compared two alternative anesthetic candidates, isoflurane and pentobarbital, with ether in terms of hematological findings, serum biochemical parameters, and gene expressions. As a result, few differences among the three agents were observed. In hematological and serum biochemistry analysis, no significant changes were found. In gene expression analysis, four known genes were extracted as differentially expressed genes in the liver of rats anesthetized with ether, isoflurane, or pentobarbital. However, no significant relationships were detected using gene ontology, pathway, or gene enrichment analyses by DAVID and TargetMine. Surprisingly, although it was expected that the lung would be affected by administration via inhalation, only one differentially expressed gene was extracted in the lung. Taken together, our data indicate that there are no significant differences among ether, isoflurane, and pentobarbital with respect to effects on hematological parameters, serum biochemistry parameters, and gene expression. Based on its smallest affect to existing data and its safety profile for humans and animals, we suggest isoflurane as a suitable alternative anesthetic for use in rat euthanasia in toxicogenomics analysis.
- Published
- 2017
- Full Text
- View/download PDF
28. Inhaled Fine Particles Induce Alveolar Macrophage Death and Interleukin-1α Release to Promote Inducible Bronchus-Associated Lymphoid Tissue Formation.
- Author
-
Kuroda E, Ozasa K, Temizoz B, Ohata K, Koo CX, Kanuma T, Kusakabe T, Kobari S, Horie M, Morimoto Y, Nakajima S, Kabashima K, Ziegler SF, Iwakura Y, Ise W, Kurosaki T, Nagatake T, Kunisawa J, Takemura N, Uematsu S, Hayashi M, Aoshi T, Kobiyama K, Coban C, and Ishii KJ
- Subjects
- Aluminum Compounds toxicity, Animals, Female, Mice, Mice, Inbred C57BL, Silicon Dioxide toxicity, Bronchi immunology, Interleukin-1alpha immunology, Lymphoid Tissue immunology, Macrophages, Alveolar pathology, Particulate Matter toxicity
- Abstract
Particulate pollution is thought to function as an adjuvant that can induce allergic responses. However, the exact cell types and immunological factors that initiate the lung-specific immune responses are unclear. We found that upon intratracheal instillation, particulates such as aluminum salts and silica killed alveolar macrophages (AMs), which then released interleukin-1α (IL-1α) and caused inducible bronchus-associated lymphoid tissue (iBALT) formation in the lung. IL-1α release continued for up to 2 weeks after particulate exposure, and type-2 allergic immune responses were induced by the inhalation of antigen during IL-1α release and iBALT formation, even long after particulate instillation. Recombinant IL-1α was sufficient to induce iBALTs, which coincided with subsequent immunoglobulin E responses, and IL-1-receptor-deficient mice failed to induce iBALT formation. Therefore, the AM-IL-1α-iBALT axis might be a therapeutic target for particulate-induced allergic inflammation., (Copyright © 2016 Elsevier Inc. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
29. Circulating nano-particulate TLR9 agonist scouts out tumor microenvironment to release immunogenic dead tumor cells.
- Author
-
Kitahata Y, Kanuma T, Hayashi M, Kobayashi N, Ozasa K, Kusakabe T, Temizoz B, Kuroda E, Yamaue H, Coban C, Yamamoto T, Kobiyama K, Aoshi T, and Ishii KJ
- Subjects
- Adjuvants, Immunologic pharmacology, Animals, Antibody Formation, CD8-Positive T-Lymphocytes immunology, CpG Islands drug effects, Cytokines pharmacology, Humans, Immunity, Innate, Interferon Type I pharmacology, Interferon-gamma immunology, Interleukin-12 immunology, Leukocyte Common Antigens metabolism, Mice, Mice, Inbred C57BL, Mice, Transgenic, Neoplasms blood, Oligodeoxyribonucleotides administration & dosage, Phagocytosis, Nanoparticles chemistry, Neoplasms immunology, Neoplasms therapy, Sizofiran pharmacology, Toll-Like Receptor 9 agonists, Tumor Microenvironment drug effects
- Abstract
Recent evidence suggest that a β-glucan derived from mushroom Schizophyllan(SPG) complexed with a humanized TLR9 agonistic CpG DNA, K3 (K3-SPG) is a promising vaccine adjuvant that induces robust CD8 T cell responses to co-administered antigen. However, it has not been investigated whether K3-SPG alone can act as an anti-cancer immunotherapeutic agent or not. Here, we demonstrate that intravenous injection of K3-SPG, but not CpG alone, is accumulated in the tumor microenvironment and triggered immunogenic cell death (ICD) of tumor cells by local induction of type-I interferon (IFN) as well as IL-12. Resultant innate immune activation as well as subsequent tumor-specific CD8 T cell responses were contributed the tumor growth suppression. This anti-tumor effect of K3-SPG monotherapy was also confirmed by using various tumor models including pancreatic cancer peritoneal dissemination model. Taken together, nano-particulate TLR9 agonist injected intravenously can scout out tumor microenvironment to provoke local innate immune activation and release dead tumor cells into circulation that may induce broader and protective tumor antigen-specific CD8 T cells., Competing Interests: K.J.I., T.A., and K.K. filed a patent application related to the current work. T.A. is an employee for the Research Foundation of Microbial Diseases of Osaka University (BIKEN). M. H. is an employee for Mitsubishi Tanabe Pharma Corporation. N.K. is an employee for Zeria Pharmaceutical Co., ltd.
- Published
- 2016
- Full Text
- View/download PDF
30. Exploring the relationship between anti-PEG IgM behaviors and PEGylated nanoparticles and its significance for accelerated blood clearance.
- Author
-
Shiraishi K, Kawano K, Maitani Y, Aoshi T, Ishii KJ, Sanada Y, Mochizuki S, Sakurai K, and Yokoyama M
- Subjects
- Animals, Half-Life, Hydrophobic and Hydrophilic Interactions, Liposomes, Male, Metabolic Clearance Rate, Mice, Inbred C57BL, Micelles, Peptides chemistry, Polyethylene Glycols chemistry, Immunoglobulin M blood, Nanoparticles chemistry, Peptides pharmacokinetics, Polyethylene Glycols pharmacokinetics
- Abstract
Surface PEGylation on nanoparticles has greatly helped prolong their blood circulation half-lives. However, The injection of PEGylated nanoparticles into mice induced poly(ethylene glycol) (PEG)-specific IgM antibodies (anti-PEG IgMs), significantly changing PEG-liposomes' pharmacokinetics. In this study, we used various PEG-conjugates to conduct a mechanistic study of anti-PEG IgMs' binding behavior. The conventional belief has been that anti-PEG IgMs bind to PEG main chains; however, our findings reveal that anti-PEG IgMs did not bind to PEG main chains, whereas anti-PEG IgMs did bind to PEG-hydrophobic polymer blocks. The insertion of a hydrophilic polymer between each PEG chain and each hydrophobic polymer block suppressed anti-PEG IgMs' binding. We prove here that hydrophobic blocks are essential to anti-PEG IgMs' binding, and also that anti-PEG IgMs do not bind to intact PEGs without hydrophobic moiety. These results support our conclusion that anti-PEG IgMs exhibit specificity to PEG; however, the presence of a hydrophobic block at a proximity position from each PEG chain is essential for the binding. Also in the present study, we elucidate relations between anti-PEG IgMs and PEGylated nanoparticles. In one of our previous studies, anti-PEG IgMs scarcely affected the pharmacokinetics of PEG-b-poly(β-benzyl l-aspartate) block copolymer (PEG-PBLA) micelles, whereas anti-PEG IgMs significantly decreased PEG-liposomes' blood circulation half-life. Finally, we found that the ratio of anti-PEG IgM molecules to PEG-liposome particles is critical to these pharmacokinetic changes, and that a 10-fold increase in the number of anti-PEG IgM molecules permitted them to capture the PEG-liposome particles, thus leading to the aforementioned changes., (Copyright © 2016 Elsevier B.V. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
31. RNA is an Adjuvanticity Mediator for the Lipid-Based Mucosal Adjuvant, Endocine.
- Author
-
Hayashi M, Aoshi T, Ozasa K, Kusakabe T, Momota M, Haseda Y, Kobari S, Kuroda E, Kobiyama K, Coban C, and Ishii KJ
- Subjects
- A549 Cells, Alarmins metabolism, Animals, Antibody Formation drug effects, Female, Humans, Inflammasomes metabolism, Lipids pharmacology, Mice, Inbred BALB C, Mice, Inbred C57BL, Mucous Membrane immunology, NLR Family, Pyrin Domain-Containing 3 Protein metabolism, Nucleic Acids metabolism, Toll-Like Receptor 2 metabolism, Toll-Like Receptor 4 metabolism, Adjuvants, Immunologic pharmacology, Lipids chemistry, Mucous Membrane drug effects, RNA pharmacology
- Abstract
Nasal vaccination has the potential to elicit systemic and mucosal immunity against pathogens. However, split and subunit vaccines lack potency at stimulating mucosal immunity, and an adjuvant is indispensable for eliciting potent mucosal immune response to nasal vaccines. Endocine, a lipid-based mucosal adjuvant, potentiates both systemic and mucosal immune responses. Although Endocine has shown efficacy and tolerability in animal and clinical studies, its mechanism of action remains unknown. It has been reported recently that endogenous danger signals are essential for the effects of some adjuvants such as alum or MF59. However, the contribution of danger signals to the adjuvanticity of Endocine has not been explored. Here, we show that RNA is likely to be an important mediator for the adjuvanticity of Endocine. Administration of Endocine generated nucleic acids release, and activated dendritic cells (DCs) in draining lymph nodes in vivo. These results suggest the possibility that Endocine indirectly activates DCs via damage-associated molecular patterns. Moreover, the adjuvanticity of Endocine disappeared in mice lacking TANK-binding kinase 1 (Tbk1), which is a downstream molecule of nucleic acid sensing signal pathway. Furthermore, co-administration of RNase A reduced the adjuvanticity of Endocine. These data suggest that RNA is important for the adjuvanticity of Endocine.
- Published
- 2016
- Full Text
- View/download PDF
32. Species-dependent role of type I IFNs and IL-12 in the CTL response induced by humanized CpG complexed with β-glucan.
- Author
-
Kobiyama K, Temizoz B, Kanuma T, Ozasa K, Momota M, Yamamoto T, Aoshi T, Kuroda E, and Ishii KJ
- Subjects
- Adjuvants, Immunologic, Adult, Animals, Cell Proliferation, Humans, Interferon-gamma immunology, Interleukin-12 deficiency, Interleukin-12 metabolism, Leukocytes, Mononuclear drug effects, Leukocytes, Mononuclear immunology, Lymphocyte Activation, Male, Mice, Oligodeoxyribonucleotides chemistry, Oligodeoxyribonucleotides pharmacology, Th1 Cells immunology, Toll-Like Receptor 9 agonists, CD8-Positive T-Lymphocytes immunology, Dendritic Cells immunology, Interferon-alpha immunology, Interleukin-12 immunology, Oligodeoxyribonucleotides immunology, beta-Glucans immunology
- Abstract
CpG oligodeoxynucleotide (ODN) is one of promising nucleic acid-based adjuvants. We recently improved its ability to enhance CD8(+) T-cell responses to coadministered protein antigen without conjugation or emulsion, by forming a nanoparticulate complex between CpG ODN (K3) and mushroom-derived β-glucan schizophyllan (SPG), namely K3-SPG. Here, we sought to elucidate the cellular immunological mechanisms by which K3-SPG induce such potent CD8(+) T-cell responses to coadministered antigen. By focusing on two DC subsets, plasmacytoid DCs and CD8α(+) DCs, as well as the secreted cytokines, IFN-α and IL-12, we found that K3-SPG strongly activates mouse plasmacytoid DCs to secrete IFN-α and CD8α(+) DCs to secrete IL-12, respectively. Although a single cytokine deficiency had no impact on adjuvant effects, the lack of both type I IFN and IL-12 in mice resulted in a significant reduction of Th1 type immune responses and CD8(+) T-cell responses elicited by protein vaccine model. By sharp contrast, type I IFN, but not IL-12, was required for the production of IFN-γ by human PBMCs as well as antigen-specific CD8(+) T-cell proliferation. Taken together, K3-SPG may overcome the species barrier for CpG ODN to enhance antigen-specific CD8(+) T-cell responses despite the differential role of IL-12 between human and mice., (© 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.)
- Published
- 2016
- Full Text
- View/download PDF
33. Monocyte infiltration into obese and fibrilized tissues is regulated by PILRα.
- Author
-
Kohyama M, Matsuoka S, Shida K, Sugihara F, Aoshi T, Kishida K, Ishii KJ, and Arase H
- Subjects
- Adipose Tissue immunology, Animals, Hepatomegaly immunology, Inflammation immunology, Liver immunology, Liver physiopathology, Liver Cirrhosis prevention & control, Macrophages immunology, Mice, Obesity prevention & control, Receptors, Immunologic deficiency, Receptors, Immunologic genetics, Liver Cirrhosis immunology, Monocytes immunology, Obesity immunology, Receptors, Immunologic physiology
- Abstract
Paired immunoglobulin-like type 2 receptor α (PILRα) is an inhibitory receptor that is mainly expressed on myeloid cells, and negatively regulates neutrophil infiltration during inflammation. However, PILRα role on monocyte has not been described. Under both steady-state and inflammatory conditions, monocytes migrate into tissues and differentiate into macrophages. Macrophages in adipose and liver tissues play important roles in tissue homeostasis and pathogenesis of metabolic diseases. Here, we found that PILRα controls monocyte mobility through regulating integrin signaling and inhibiting CD99-CD99 binding. Moreover, we found that Pilra(-/-) mice developed obesity and hepatomegaly with fibrosis, and the numbers of macrophages in adipose and liver tissues are significantly increased in Pilra(-/-) mice. These data suggest that immune inhibitory receptor, PILRα, plays an important role in the prevention of obesity and liver fibrosis., (© 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.)
- Published
- 2016
- Full Text
- View/download PDF
34. Optimization of physiological properties of hydroxyapatite as a vaccine adjuvant.
- Author
-
Hayashi M, Aoshi T, Kogai Y, Nomi D, Haseda Y, Kuroda E, Kobiyama K, and Ishii KJ
- Subjects
- Adjuvants, Immunologic administration & dosage, Animals, Durapatite administration & dosage, Female, Mice, Inbred C57BL, Nanoparticles administration & dosage, Vaccines administration & dosage, Adjuvants, Immunologic pharmacology, Chemical Phenomena, Durapatite pharmacology, Vaccines immunology
- Abstract
Various particles such as Alum or silica are known to act as an adjuvant if co-administered with vaccine antigens. Several reports have demonstrated that the adjuvanticity is strongly affected by the physicochemical properties of particles such as the size, shape and surface charge, although the required properties and its relationship to the adjuvanticity are still controversial. Hydroxyapatite particle (HAp) composed of calcium phosphate has been shown to work as adjuvant in mice. However, the properties of HAp required for the adjuvanticity have not been fully characterized yet. In this study, we examined the role of size or shape of HAps in the antibody responses after immunization with antigen. HAps whose diameter ranging between 100 and 400 nm provided significantly higher antibody responses than smaller or larger ones. By comparison between sphere and rod shaped HAps, rod shaped HAps induced stronger inflammasome-dependent IL-1β production than the sphere shaped ones in vitro. However, sphere- and rod-shaped HAp elicited comparable antibody response in WT mice. Vice versa, Nlrp3(-/-), Asc(-/-) or Caspase1(-/-) mice provided comparable level of antibody responses to HAp adjuvanted vaccination. Collectively, our results demonstrated that the size rather than shape is a more critical property, and IL-1β production via NLRP3 inflammasome is dispensable for the adjuvanticity of HAps in mice., (Copyright © 2015 Elsevier Ltd. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
35. Immunization with antigenic peptides complexed with β-glucan induces potent cytotoxic T-lymphocyte activity in combination with CpG-ODNs.
- Author
-
Mochizuki S, Morishita H, Kobiyama K, Aoshi T, Ishii KJ, and Sakurai K
- Subjects
- Adjuvants, Immunologic pharmacokinetics, Animals, Antigen-Presenting Cells drug effects, Antigen-Presenting Cells immunology, Antigen-Presenting Cells metabolism, Cancer Vaccines immunology, Cancer Vaccines pharmacokinetics, Cells, Cultured, Lymphocytes, Tumor-Infiltrating immunology, Lymphocytes, Tumor-Infiltrating metabolism, Lymphocytes, Tumor-Infiltrating pathology, Mice, Inbred C57BL, Neoplasms immunology, Neoplasms metabolism, Neoplasms pathology, Oligodeoxyribonucleotides immunology, Oligodeoxyribonucleotides pharmacokinetics, Ovalbumin immunology, Ovalbumin pharmacokinetics, Peptide Fragments administration & dosage, Peptide Fragments immunology, Peptide Fragments pharmacokinetics, Sizofiran immunology, Sizofiran pharmacokinetics, Spleen drug effects, Spleen immunology, Spleen metabolism, T-Lymphocytes, Cytotoxic immunology, T-Lymphocytes, Cytotoxic metabolism, Tissue Distribution, Tumor Burden drug effects, Adjuvants, Immunologic administration & dosage, Cancer Vaccines administration & dosage, Immunization, Lymphocyte Activation drug effects, Lymphocytes, Tumor-Infiltrating drug effects, Neoplasms drug therapy, Oligodeoxyribonucleotides administration & dosage, Ovalbumin administration & dosage, Sizofiran administration & dosage, T-Lymphocytes, Cytotoxic drug effects
- Abstract
The induction of antigen-specific immune responses requires immunization with not only antigens, but also adjuvants. CpG oligonucleotides (CpG-ODNs) are well-known ligands for Toll-like receptor 9 and a potent adjuvant that induces both Th1-type humoral and cellular immune responses including cytotoxic T-lymphocyte responses. We previously demonstrated that β-glucan schizophyllan (SPG) can form complexes with CpG-ODNs with attached dA40 (CpG-dA/SPG), which can accumulate in macrophages in the draining inguinal lymph nodes and induce strong immune responses by co-administration of antigenic proteins, namely ovalbumin (OVA). Immunization with antigenic peptides, OVA257-264, did not induce these antigen-specific immune responses even in combination with CpG-dA/SPG, indicating that peptides require a carrier to antigen presenting cells. In this study, we prepared conjugates comprising OVA257-264 and dA40, and made complexes with SPG. Immunization with OVA257-264-dA/SPG induced peptide-specific immune responses in combination with CpG-dA regardless of complexation with SPG both in vitro and in vivo. When splenocytes from immunized mice were incubated with E.G7-OVA tumor model cells presenting OVA peptides, the number of cells drastically decreased after 24h. Furthermore, mice pre-immunized with OVA257-264-dA/SPG and CpG-ODNs exhibited a long delay in tumor growth after tumor inoculation. Therefore, these peptide-dA/SPG and CpG-dA/SPG complexes could be used as a potent vaccine for the treatment of cancers and infectious diseases., (Copyright © 2015 Elsevier B.V. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
36. TLR9 and STING agonists synergistically induce innate and adaptive type-II IFN.
- Author
-
Temizoz B, Kuroda E, Ohata K, Jounai N, Ozasa K, Kobiyama K, Aoshi T, and Ishii KJ
- Subjects
- Adjuvants, Immunologic pharmacology, Animals, Cell Line, Tumor, Drug Synergism, Female, Immunoglobulin G biosynthesis, Immunoglobulin G immunology, Interferon Regulatory Factor-3 metabolism, Interferon Regulatory Factor-7 metabolism, Interferon Type I metabolism, Interferon-gamma immunology, Interleukin-12 metabolism, Mice, Mice, Inbred C57BL, Mice, Knockout, Myeloid Differentiation Factor 88 metabolism, Interferon-gamma biosynthesis, Membrane Proteins agonists, Neoplasms therapy, Nucleotides, Cyclic pharmacology, Oligodeoxyribonucleotides pharmacology, T-Lymphocytes, Cytotoxic immunology, Toll-Like Receptor 9 agonists
- Abstract
Agonists for TLR9 and Stimulator of IFN Gene (STING) act as vaccine adjuvants that induce type-1 immune responses. However, currently available CpG oligodeoxynucleotide (ODN) (K-type) induces IFNs only weakly and STING ligands rather induce type-2 immune responses, limiting their potential therapeutic applications. Here, we show a potent synergism between TLR9 and STING agonists. Together, they make an effective type-1 adjuvant and an anticancer agent. The synergistic effect between CpG ODN (K3) and STING-ligand cyclic GMP-AMP (cGAMP), culminating in NK cell IFN-γ (type-II IFN) production, is due to the concurrent effects of IL-12 and type-I IFNs, which are differentially regulated by IRF3/7, STING, and MyD88. The combination of CpG ODN with cGAMP is a potent type-1 adjuvant, capable of inducing strong Th 1-type responses, as demonstrated by enhanced antigen-specific IgG2c and IFN-γ production, as well as cytotoxic CD8(+) T-cell responses. In our murine tumor models, intratumoral injection of CpG ODN and cGAMP together reduced tumor size significantly compared with the singular treatments, acting as an antigen-free anticancer agent. Thus, the combination of CpG ODN and a STING ligand may offer therapeutic application as a potent type-II IFN inducer., (© 2014 The Authors. European Journal of Immunology published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.)
- Published
- 2015
- Full Text
- View/download PDF
37. RNA polymerase III regulates cytosolic RNA:DNA hybrids and intracellular microRNA expression.
- Author
-
Koo CX, Kobiyama K, Shen YJ, LeBert N, Ahmad S, Khatoo M, Aoshi T, Gasser S, and Ishii KJ
- Subjects
- Base Sequence, Cell Line, Tumor, Cytosol metabolism, DNA Damage, Humans, Mass Spectrometry, Oligonucleotide Array Sequence Analysis, RNA, Small Interfering, DNA genetics, MicroRNAs genetics, Nucleic Acid Hybridization, RNA genetics, RNA Polymerase III metabolism
- Abstract
RNA:DNA hybrids form in the nuclei and mitochondria of cells as transcription-induced R-loops or G-quadruplexes, but exist only in the cytosol of virus-infected cells. Little is known about the existence of RNA:DNA hybrids in the cytosol of virus-free cells, in particular cancer or transformed cells. Here, we show that cytosolic RNA:DNA hybrids are present in various human cell lines, including transformed cells. Inhibition of RNA polymerase III (Pol III), but not DNA polymerase, abrogated cytosolic RNA:DNA hybrids. Cytosolic RNA:DNA hybrids bind to several components of the microRNA (miRNA) machinery-related proteins, including AGO2 and DDX17. Furthermore, we identified miRNAs that are specifically regulated by Pol III, providing a potential link between RNA:DNA hybrids and the miRNA machinery. One of the target genes, exportin-1, is shown to regulate cytosolic RNA:DNA hybrids. Taken together, we reveal previously unknown mechanism by which Pol III regulates the presence of cytosolic RNA:DNA hybrids and miRNA biogenesis in various human cells., (© 2015 by The American Society for Biochemistry and Molecular Biology, Inc.)
- Published
- 2015
- Full Text
- View/download PDF
38. Hydroxypropyl-β-cyclodextrin spikes local inflammation that induces Th2 cell and T follicular helper cell responses to the coadministered antigen.
- Author
-
Onishi M, Ozasa K, Kobiyama K, Ohata K, Kitano M, Taniguchi K, Homma T, Kobayashi M, Sato A, Katakai Y, Yasutomi Y, Wijaya E, Igarashi Y, Nakatsu N, Ise W, Inoue T, Yamada H, Vandenbon A, Standley DM, Kurosaki T, Coban C, Aoshi T, Kuroda E, and Ishii KJ
- Subjects
- 2-Hydroxypropyl-beta-cyclodextrin, Adjuvants, Immunologic administration & dosage, Animals, Antibody Formation drug effects, Antibody Formation genetics, Antibody Formation immunology, Antigens administration & dosage, Host-Pathogen Interactions drug effects, Host-Pathogen Interactions immunology, Inflammation genetics, Influenza A Virus, H1N1 Subtype immunology, Influenza A Virus, H1N1 Subtype physiology, Influenza Vaccines administration & dosage, Influenza Vaccines immunology, Lymph Nodes drug effects, Lymph Nodes immunology, Lymph Nodes metabolism, Macaca fascicularis, Male, Mice, Inbred C57BL, Mice, Knockout, Microscopy, Fluorescence, Multiphoton, Oligonucleotide Array Sequence Analysis, Orthomyxoviridae Infections immunology, Orthomyxoviridae Infections prevention & control, Orthomyxoviridae Infections virology, Spleen drug effects, Spleen immunology, Spleen metabolism, T-Lymphocytes, Helper-Inducer drug effects, T-Lymphocytes, Helper-Inducer metabolism, Th2 Cells drug effects, Th2 Cells metabolism, Transcriptome drug effects, Transcriptome immunology, beta-Cyclodextrins administration & dosage, Antigens immunology, Inflammation immunology, T-Lymphocytes, Helper-Inducer immunology, Th2 Cells immunology, beta-Cyclodextrins immunology
- Abstract
Cyclodextrins are commonly used as a safe excipient to enhance the solubility and bioavailability of hydrophobic pharmaceutical agents. Their efficacies and mechanisms as drug-delivery systems have been investigated for decades, but their immunological properties have not been examined. In this study, we reprofiled hydroxypropyl-β-cyclodextrin (HP-β-CD) as a vaccine adjuvant and found that it acts as a potent and unique adjuvant. HP-β-CD triggered the innate immune response at the injection site, was trapped by MARCO(+) macrophages, increased Ag uptake by dendritic cells, and facilitated the generation of T follicular helper cells in the draining lymph nodes. It significantly enhanced Ag-specific Th2 and IgG Ab responses as potently as did the conventional adjuvant, aluminum salt (alum), whereas its ability to induce Ag-specific IgE was less than that of alum. At the injection site, HP-β-CD induced the temporary release of host dsDNA, a damage-associated molecular pattern. DNase-treated mice, MyD88-deficient mice, and TBK1-deficient mice showed significantly reduced Ab responses after immunization with this adjuvant. Finally, we demonstrated that HP-β-CD-adjuvanted influenza hemagglutinin split vaccine protected against a lethal challenge with a clinically isolated pandemic H1N1 influenza virus, and the adjuvant effect of HP-β-CD was demonstrated in cynomolgus macaques. Our results suggest that HP-β-CD acts as a potent MyD88- and TBK1-dependent T follicular helper cell adjuvant and is readily applicable to various vaccines., (Copyright © 2015 by The American Association of Immunologists, Inc.)
- Published
- 2015
- Full Text
- View/download PDF
39. Development of Nonaggregating Poly-A Tailed Immunostimulatory A/D Type CpG Oligodeoxynucleotides Applicable for Clinical Use.
- Author
-
Aoshi T, Haseda Y, Kobiyama K, Narita H, Sato H, Nankai H, Mochizuki S, Sakurai K, Katakai Y, Yasutomi Y, Kuroda E, Coban C, and Ishii KJ
- Subjects
- Animals, Cytokines biosynthesis, Dose-Response Relationship, Drug, Dose-Response Relationship, Immunologic, Fatty Acids, Monounsaturated chemistry, Humans, Influenza Vaccines immunology, Leukocytes, Mononuclear drug effects, Leukocytes, Mononuclear immunology, Leukocytes, Mononuclear metabolism, Macaca fascicularis, Oligodeoxyribonucleotides administration & dosage, Oligodeoxyribonucleotides chemistry, Quaternary Ammonium Compounds chemistry, Solubility, Adjuvants, Immunologic, Oligodeoxyribonucleotides immunology, Poly A chemistry
- Abstract
Immunostimulatory CpG ODNs have been developed and utilized as TLR9-dependent innate immune activators and vaccine adjuvants. Four different types of immunostimulatory CpG ODNs (A/D, B/K, C, and P type) have been reported. A/D type ODNs are characterized by high IFN-α production but intrinsically form aggregates, hindering its good manufacturing practice grade preparation. In this study, we developed several D35-derived ODNs (a commonly used A/D type ODN), which were modified with the addition of a phosphorothioate polynucleotide tail (such as dAs40), and examined their physical properties, solubility in saline, immunostimulatory activity on human PBMCs, and vaccine adjuvant potential in monkeys. We found that two modified ODNs including D35-dAs40 and D35core-dAs40 were immunostimulatory, similar to original D35 in human PBMCs, resulting in high IFN-α secretion in a dose-dependent manner. Physical property analysis by dynamic light scattering revealed that both D35-dAs40 and D35core-dAs40 did not form aggregates in saline, which is currently impossible for the original D35. Furthermore, D35-dAs40 and D35core-dAs40 worked as better vaccine adjuvant in monkeys. These results suggested that D35-dAs40 and D35core-dAs40 are two promising prototypes of nonaggregating A/D type ODN with advantages of ease of drug preparation for clinical applications as vaccine adjuvants or IFN-α inducing immunomodifiers.
- Published
- 2015
- Full Text
- View/download PDF
40. Protective epitopes of the Plasmodium falciparum SERA5 malaria vaccine reside in intrinsically unstructured N-terminal repetitive sequences.
- Author
-
Yagi M, Bang G, Tougan T, Palacpac NM, Arisue N, Aoshi T, Matsumoto Y, Ishii KJ, Egwang TG, Druilhe P, and Horii T
- Subjects
- Adolescent, Adult, Animals, Child, Epitopes chemistry, Humans, Malaria, Falciparum prevention & control, Saimiri, Young Adult, Epitopes immunology, Malaria Vaccines immunology, Plasmodium falciparum immunology
- Abstract
The malaria vaccine candidate antigen, SE36, is based on the N-terminal 47 kDa domain of Plasmodium falciparum serine repeat antigen 5 (SERA5). In epidemiological studies, we have previously shown the inhibitory effects of SE36 specific antibodies on in vitro parasite growth and the negative correlation between antibody level and malaria symptoms. A phase 1 b trial of the BK-SE36 vaccine in Uganda elicited 72% protective efficacy against symptomatic malaria in children aged 6-20 years during the follow-up period 130-365 days post-second vaccination. Here, we performed epitope mapping with synthetic peptides covering the whole sequence of SE36 to identify and map dominant epitopes in Ugandan adult serum presumed to have clinical immunity to P. falciparum malaria. High titer sera from the Ugandan adults predominantly reacted with peptides corresponding to two successive N-terminal regions of SERA5 containing octamer repeats and serine rich sequences, regions of SERA5 that were previously reported to have limited polymorphism. Affinity purified antibodies specifically recognizing the octamer repeats and serine rich sequences exhibited a high antibody-dependent cellular inhibition (ADCI) activity that inhibited parasite growth. Furthermore, protein structure predictions and structural analysis of SE36 using spectroscopic methods indicated that N-terminal regions possessing inhibitory epitopes are intrinsically unstructured. Collectively, these results suggest that strict tertiary structure of SE36 epitopes is not required to elicit protective antibodies in naturally immune Ugandan adults.
- Published
- 2014
- Full Text
- View/download PDF
41. Olfactory plays a key role in spatiotemporal pathogenesis of cerebral malaria.
- Author
-
Zhao H, Aoshi T, Kawai S, Mori Y, Konishi A, Ozkan M, Fujita Y, Haseda Y, Shimizu M, Kohyama M, Kobiyama K, Eto K, Nabekura J, Horii T, Ishino T, Yuda M, Hemmi H, Kaisho T, Akira S, Kinoshita M, Tohyama K, Yoshioka Y, Ishii KJ, and Coban C
- Subjects
- Animals, CD8-Positive T-Lymphocytes immunology, Chemokine CCL21 genetics, Chemokine CCL21 immunology, Female, Humans, Malaria, Cerebral genetics, Malaria, Cerebral immunology, Malaria, Cerebral pathology, Male, Mice, Mice, Inbred C57BL, Olfactory Bulb immunology, Olfactory Bulb pathology, Plasmodium falciparum pathogenicity, Receptors, CCR7 genetics, Receptors, CCR7 immunology, Receptors, CXCR3 genetics, Receptors, CXCR3 immunology, Virulence, Malaria, Cerebral parasitology, Olfactory Bulb parasitology, Plasmodium falciparum physiology
- Abstract
Cerebral malaria is a complication of Plasmodium falciparum infection characterized by sudden coma, death, or neurodisability. Studies using a mouse model of experimental cerebral malaria (ECM) have indicated that blood-brain barrier disruption and CD8 T cell recruitment contribute to disease, but the spatiotemporal mechanisms are poorly understood. We show by ultra-high-field MRI and multiphoton microscopy that the olfactory bulb is physically and functionally damaged (loss of smell) by Plasmodium parasites during ECM. The trabecular small capillaries comprising the olfactory bulb show parasite accumulation and cell occlusion followed by microbleeding, events associated with high fever and cytokine storm. Specifically, the olfactory upregulates chemokine CCL21, and loss or functional blockade of its receptors CCR7 and CXCR3 results in decreased CD8 T cell activation and recruitment, respectively, as well as prolonged survival. Thus, early detection of olfaction loss and blockade of pathological cell recruitment may offer potential therapeutic strategies for ECM., (Copyright © 2014 Elsevier Inc. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
42. Blockade of TLR3 protects mice from lethal radiation-induced gastrointestinal syndrome.
- Author
-
Takemura N, Kawasaki T, Kunisawa J, Sato S, Lamichhane A, Kobiyama K, Aoshi T, Ito J, Mizuguchi K, Karuppuchamy T, Matsunaga K, Miyatake S, Mori N, Tsujimura T, Satoh T, Kumagai Y, Kawai T, Standley DM, Ishii KJ, Kiyono H, Akira S, and Uematsu S
- Subjects
- Animals, Apoptosis, Female, Gastrointestinal Diseases genetics, Gastrointestinal Diseases physiopathology, Humans, Mice, Mice, Inbred BALB C, Mice, Knockout, Radiation Injuries genetics, Radiation Injuries physiopathology, Radiation, Ionizing, Toll-Like Receptor 3 genetics, Tumor Suppressor Protein p53 genetics, Tumor Suppressor Protein p53 metabolism, Gastrointestinal Diseases metabolism, Gastrointestinal Diseases prevention & control, Radiation Injuries metabolism, Radiation Injuries prevention & control, Toll-Like Receptor 3 deficiency
- Abstract
High-dose ionizing radiation induces severe DNA damage in the epithelial stem cells in small intestinal crypts and causes gastrointestinal syndrome (GIS). Although the tumour suppressor p53 is a primary factor inducing death of crypt cells with DNA damage, its essential role in maintaining genome stability means inhibiting p53 to prevent GIS is not a viable strategy. Here we show that the innate immune receptor Toll-like receptor 3 (TLR3) is critical for the pathogenesis of GIS. Tlr3(-/-) mice show substantial resistance to GIS owing to significantly reduced radiation-induced crypt cell death. Despite showing reduced crypt cell death, p53-dependent crypt cell death is not impaired in Tlr3(-/-) mice. p53-dependent crypt cell death causes leakage of cellular RNA, which induces extensive cell death via TLR3. An inhibitor of TLR3-RNA binding ameliorates GIS by reducing crypt cell death. Thus, we propose blocking TLR3 activation as a novel approach to treat GIS.
- Published
- 2014
- Full Text
- View/download PDF
43. Nonagonistic Dectin-1 ligand transforms CpG into a multitask nanoparticulate TLR9 agonist.
- Author
-
Kobiyama K, Aoshi T, Narita H, Kuroda E, Hayashi M, Tetsutani K, Koyama S, Mochizuki S, Sakurai K, Katakai Y, Yasutomi Y, Saijo S, Iwakura Y, Akira S, Coban C, and Ishii KJ
- Subjects
- Adjuvants, Immunologic pharmacology, Animals, Cells, Cultured, Enzyme-Linked Immunosorbent Assay, Humans, Interferon Inducers pharmacology, Lectins, C-Type genetics, Leukocytes, Mononuclear drug effects, Leukocytes, Mononuclear metabolism, Mice, Mice, Inbred C57BL, Microscopy, Electron, Oligodeoxyribonucleotides genetics, Oligodeoxyribonucleotides metabolism, CpG Islands genetics, Immunotherapy methods, Lectins, C-Type metabolism, Nanoparticles metabolism, Oligodeoxyribonucleotides pharmacology, Sizofiran metabolism, Toll-Like Receptor 9 agonists
- Abstract
CpG DNA, a ligand for Toll-like receptor 9 (TLR9), has been one of the most promising immunotherapeutic agents. Although there are several types of potent humanized CpG oligodeoxynucleotide (ODN), developing "all-in-one" CpG ODNs activating both B cells and plasmacytoid dendritic cells forming a stable nanoparticle without aggregation has not been successful. In this study, we generated a novel nanoparticulate K CpG ODN (K3) wrapped by the nonagonistic Dectin-1 ligand schizophyllan (SPG), K3-SPG. In sharp contrast to K3 alone, K3-SPG stimulates human peripheral blood mononuclear cells to produce a large amount of both type I and type II IFN, targeting the same endosome where IFN-inducing D CpG ODN resides without losing its K-type activity. K3-SPG thus became a potent adjuvant for induction of both humoral and cellular immune responses, particularly CTL induction, to coadministered protein antigens without conjugation. Such potent adjuvant activity of K3-SPG is attributed to its nature of being a nanoparticle rather than targeting Dectin-1 by SPG, accumulating and activating antigen-bearing macrophages and dendritic cells in the draining lymph node. K3-SPG acting as an influenza vaccine adjuvant was demonstrated in vivo in both murine and nonhuman primate models. Taken together, K3-SPG may be useful for immunotherapeutic applications that require type I and type II IFN as well as CTL induction.
- Published
- 2014
- Full Text
- View/download PDF
44. Innate Immune Signaling by, and Genetic Adjuvants for DNA Vaccination.
- Author
-
Kobiyama K, Jounai N, Aoshi T, Tozuka M, Takeshita F, Coban C, and Ishii KJ
- Abstract
DNA vaccines can induce both humoral and cellular immune responses. Although some DNA vaccines are already licensed for infectious diseases in animals, they are not licensed for human use because the risk and benefit of DNA vaccines is still controversial. Indeed, in humans, the immunogenicity of DNA vaccines is lower than that of other traditional vaccines. To develop the use of DNA vaccines in the clinic, various approaches are in progress to enhance or improve the immunogenicity of DNA vaccines. Recent studies have shown that immunogenicity of DNA vaccines are regulated by innate immune responses via plasmid DNA recognition through the STING-TBK1 signaling cascade. Similarly, molecules that act as dsDNA sensors that activate innate immune responses through STING-TBK1 have been identified and used as genetic adjuvants to enhance DNA vaccine immunogenicity in mouse models. However, the mechanisms that induce innate immune responses by DNA vaccines are still unclear. In this review, we will discuss innate immune signaling upon DNA vaccination and genetic adjuvants of innate immune signaling molecules.
- Published
- 2013
- Full Text
- View/download PDF
45. Hydrophobic blocks of PEG-conjugates play a significant role in the accelerated blood clearance (ABC) phenomenon.
- Author
-
Shiraishi K, Hamano M, Ma H, Kawano K, Maitani Y, Aoshi T, Ishii KJ, and Yokoyama M
- Subjects
- Animals, Enzyme-Linked Immunosorbent Assay, Gadolinium administration & dosage, Gadolinium chemistry, Hydrophobic and Hydrophilic Interactions, Immunoglobulin G blood, Immunoglobulin M blood, Kidney metabolism, Liver metabolism, Male, Metabolic Clearance Rate, Mice, Mice, Inbred BALB C, Mice, Inbred C57BL, Polyethylene Glycols administration & dosage, Polyethylene Glycols chemistry, Spleen metabolism, Gadolinium pharmacokinetics, Liposomes, Micelles, Polyethylene Glycols pharmacokinetics
- Abstract
Injections of poly(ethylene glycol)-modified liposomes (PEG-liposomes) cause rapid clearance of the second dose of PEG-liposomes. This phenomenon is known as the accelerated blood clearance (ABC) phenomenon. Previous studies have suggested that PEG-specific IgM (anti-PEG IgM) can play a major role in the ABC phenomenon. In our previous study, however, a PEG-shell-possessing polymeric micelle with hydrophilic inner core (PEG-P(Lys-DOTA-Gd) micelle) did not induce the ABC phenomenon nor the IgM responses, and exhibited no change in its plasma concentration in PEG-liposome-injected mice. In the present paper, we studied the ABC-phenomenon in more detail by comparing the behaviors between PEG-liposomes, PEG-P(Lys-DOTA-Gd) micelle, and hydrophobic-core-possessing PEG-PBLA micelles. We demonstrated that the PEG-PBLA micelle induced similar IgM responses as observed in PEG-liposome; however, the second dose of PEG-PBLA micelle exhibited no decreases in their plasma concentration, while the second dose of PEG-liposome did exhibit rapid clearances. Furthermore, we did not observe any PEG main chain specific IgM in PEG-liposome injected mice by sandwich ELISA which can measure more specific IgM to the PEG main chain theoretically. These results suggested that the induced IgM recognizes an interface between PEG chain and hydrophobic chain, rather than PEG main chain, and the anti-PEG IgM hypothesis should be re-evaluated., (Copyright © 2012 Elsevier B.V. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
46. TLR9 adjuvants enhance immunogenicity and protective efficacy of the SE36/AHG malaria vaccine in nonhuman primate models.
- Author
-
Tougan T, Aoshi T, Coban C, Katakai Y, Kai C, Yasutomi Y, Ishii KJ, and Horii T
- Subjects
- Adjuvants, Immunologic administration & dosage, Animals, Antibodies, Protozoan blood, Disease Models, Animal, Hemeproteins administration & dosage, Immunoglobulin G blood, Leukocytes, Mononuclear immunology, Macaca fascicularis, Malaria Vaccines administration & dosage, Malaria, Falciparum immunology, Oligodeoxyribonucleotides administration & dosage, Parasitemia prevention & control, Saimiri, Adjuvants, Immunologic adverse effects, Hemeproteins adverse effects, Malaria Vaccines adverse effects, Malaria Vaccines immunology, Malaria, Falciparum prevention & control, Oligodeoxyribonucleotides adverse effects, Toll-Like Receptor 9 agonists
- Abstract
The SE36 antigen, derived from serine repeat antigen 5 (SERA5) of Plasmodium falciparum, is a promising blood stage malaria vaccine candidate. Ongoing clinical trials suggest the efficacy of the SE36 vaccine could be increased by the incorporation of more effective adjuvants into the vaccine formulation. In this study, we assessed the safety, immunogenicity and protective efficacy of SE36/AHG formulated with TLR9 ligand adjuvants K3 CpG oligodeoxyribonucleotides (CpG ODNs) (K3 ODN), D3 ODN or synthetic hemozoin, in two non-human primate models. SE36/AHG with or without each adjuvant was administrated to cynomolgus monkeys. A combination of TLR9 ligand adjuvant with SE36/AHG induced higher humoral and cellular immune response compared with SE36/AHG alone. Administration of a crude extract of P. falciparum parasite resulted in the induction of more SE36-specific IgG antibodies in monkeys vaccinated with a combination of SE36/AHG and adjuvant, as opposed to vaccination with SE36/AHG alone. The most effective TLR9 ligand, K3 ODN, was chosen for further vaccine trials in squirrel monkeys, in combination with SE36/AHG. All monkeys immunized with the combined SE36/AHG and K3 ODN formulation effectively suppressed parasitemia and symptoms of malaria following challenge infections. Furthermore, no serious adverse events were observed. Our results show that the novel vaccine formulation of K3 ODN with SE36/AHG demonstrates safety, potent immunogenicity and efficacy in nonhuman primates, and this vaccine formulation may form the basis of a more effective malaria vaccine.
- Published
- 2013
- Full Text
- View/download PDF
47. The chemotherapeutic agent DMXAA as a unique IRF3-dependent type-2 vaccine adjuvant.
- Author
-
Tang CK, Aoshi T, Jounai N, Ito J, Ohata K, Kobiyama K, Dessailly BH, Kuroda E, Akira S, Mizuguchi K, Coban C, and Ishii KJ
- Subjects
- Animals, Enzyme-Linked Immunosorbent Assay, Female, Immunity, Innate drug effects, Interferon Regulatory Factor-3 genetics, Interleukin-33, Interleukins genetics, Interleukins metabolism, Male, Mice, Mice, Knockout, Adjuvants, Immunologic therapeutic use, Interferon Regulatory Factor-3 metabolism, Xanthones therapeutic use
- Abstract
5,6-Dimethylxanthenone-4-acetic acid (DMXAA), a potent type I interferon (IFN) inducer, was evaluated as a chemotherapeutic agent in mouse cancer models and proved to be well tolerated in human cancer clinical trials. Despite its multiple biological functions, DMXAA has not been fully characterized for the potential application as a vaccine adjuvant. In this report, we show that DMXAA does act as an adjuvant due to its unique property as a soluble innate immune activator. Using OVA as a model antigen, DMXAA was demonstrated to improve on the antigen specific immune responses and induce a preferential Th2 (Type-2) response. The adjuvant effect was directly dependent on the IRF3-mediated production of type-I-interferon, but not IL-33. DMXAA could also enhance the immunogenicity of influenza split vaccine which led to significant increase in protective responses against live influenza virus challenge in mice compared to split vaccine alone. We propose that DMXAA can be used as an adjuvant that targets a specific innate immune signaling pathway via IRF3 for potential applications including vaccines against influenza which requires a high safety profile.
- Published
- 2013
- Full Text
- View/download PDF
48. Lipocalin 2 bolsters innate and adaptive immune responses to blood-stage malaria infection by reinforcing host iron metabolism.
- Author
-
Zhao H, Konishi A, Fujita Y, Yagi M, Ohata K, Aoshi T, Itagaki S, Sato S, Narita H, Abdelgelil NH, Inoue M, Culleton R, Kaneko O, Nakagawa A, Horii T, Akira S, Ishii KJ, and Coban C
- Subjects
- Adaptive Immunity, Animals, Erythrocytes parasitology, Granulocytes immunology, Granulocytes metabolism, Granulocytes parasitology, Homeostasis, Host-Parasite Interactions, Humans, Immunity, Innate, Lipocalin-2, Lipocalins blood, Macrophages immunology, Macrophages metabolism, Macrophages parasitology, Malaria blood, Malaria parasitology, Malaria, Vivax blood, Malaria, Vivax immunology, Malaria, Vivax metabolism, Malaria, Vivax parasitology, Mice, Mice, Inbred BALB C, Mice, Inbred C57BL, Mice, Knockout, Parasitemia blood, Parasitemia immunology, Parasitemia parasitology, Plasmodium vivax immunology, Plasmodium yoelii immunology, Proto-Oncogene Proteins blood, Reticulocytosis, Acute-Phase Proteins metabolism, Iron metabolism, Lipocalins metabolism, Malaria immunology, Malaria metabolism, Proto-Oncogene Proteins metabolism
- Abstract
Plasmodium parasites multiply within host erythrocytes, which contain high levels of iron, and parasite egress from these cells results in iron release and host anemia. Although Plasmodium requires host iron for replication, how host iron homeostasis and responses to these fluxes affect Plasmodium infection are incompletely understood. We determined that Lipocalin 2 (Lcn2), a host protein that sequesters iron, is abundantly secreted during human (P. vivax) and mouse (P. yoeliiNL) blood-stage malaria infections and is essential to control P. yoeliiNL parasitemia, anemia, and host survival. During infection, Lcn2 bolsters both host macrophage function and granulocyte recruitment and limits reticulocytosis, or the expansion of immature erythrocytes, which are the preferred target cell of P. yoeliiNL. Additionally, a chronic iron imbalance due to Lcn2 deficiency results in impaired adaptive immune responses against Plasmodium parasites. Thus, Lcn2 exerts antiparasitic effects by maintaining iron homeostasis and promoting innate and adaptive immune responses., (Copyright © 2012 Elsevier Inc. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
49. Novel strategies to improve DNA vaccine immunogenicity.
- Author
-
Coban C, Kobiyama K, Aoshi T, Takeshita F, Horii T, Akira S, and Ishii KJ
- Subjects
- Adjuvants, Immunologic genetics, Animals, Antigens, Protozoan immunology, DNA metabolism, Dendritic Cells immunology, Humans, Immunity, Humoral genetics, Inflammasomes genetics, Inflammasomes immunology, Membrane Proteins genetics, Membrane Proteins metabolism, Protein Serine-Threonine Kinases genetics, Protein Serine-Threonine Kinases metabolism, Signal Transduction, Vaccines, DNA genetics, Vaccines, DNA immunology
- Abstract
DNA vaccines can induce both humoral and cellular immune responses in animals. Some DNA vaccines are already licensed for infectious diseases such as West Nile virus encephalitis in horses. When used in humans, however, DNA vaccines suffer from lower immunogenicity profiles. Although the reasons for this are poorly understood, various hypotheses have been proposed. This review aims to provide better understanding of the molecular and immunological mechanisms by which DNA vaccines work and how such knowledge can be used to bring about improvements in their efficacy. Recent studies have provided evidence that the 'adjuvant effect' of plasmid DNA is mediated by its double-stranded structure. This structure activates stimulator of interferon genes/TANK-binding kinase 1 (STING/TBK1)- dependent innate immune signaling pathways in the absence of Toll-like receptors. Indeed, type-I interferons (IFNs), induced in vivo via the STING/TBK1 pathway, were found to be crucial for both direct- and indirect-antigen presentation via distinct cell types (i.e. dendritic cells (DC) and muscle cells, respectively). Importantly, incorporation of TBK1 into a DNA vaccine was found to enhance the antigen-specific humoral immune responses targeting the Plasmodium falciparum serine repeat antigen (SERA), a candidate vaccine antigen expressed in the blood-stages of human malaria parasites. Thus, the results of these studies may offer new ways to develop DNA vaccines, as well as delivering novel vaccine adjuvants against infectious diseases.
- Published
- 2011
- Full Text
- View/download PDF
50. Innate and adaptive immune responses to viral infection and vaccination.
- Author
-
Aoshi T, Koyama S, Kobiyama K, Akira S, and Ishii KJ
- Subjects
- Animals, Humans, Influenza, Human immunology, Influenza, Human prevention & control, Influenza, Human virology, Orthomyxoviridae genetics, Orthomyxoviridae immunology, Receptors, Immunologic genetics, Receptors, Immunologic immunology, Vaccination, Virus Diseases prevention & control, Virus Diseases virology, Viruses genetics, Adaptive Immunity, Immunity, Innate, Virus Diseases immunology, Viruses immunology
- Abstract
Recent accumulating evidence suggests that the human immune system possesses a variety of innate receptors that recognize, distinguish, and respond to viral infections and to vaccination. These include Toll-like receptors, C-type lectin receptors, RIG-I-like receptors, Nod-like receptors and possibly AIM2-like receptors. However, the precise mechanisms by which these receptors exert their critical roles in the induction of virus-specific adaptive immune responses have not been fully elucidated. In this review, we discuss recent advances in our understanding of the innate immune recognition of viruses and the differential connection to the adaptive immune responses induced by infection or vaccination, with a particular focus on the influenza virus., (Copyright © 2011 Elsevier B.V. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.